[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 4811
1. Mancuso M, Leonardi S, Tanori M, Pasquali E, Pierdomenico M, Rebessi S, Di Majo V, Covelli V, Pazzaglia S, Saran A: Hair cycle-dependent basal cell carcinoma tumorigenesis in Ptc1neo67/+ mice exposed to radiation. Cancer Res; 2006 Jul 1;66(13):6606-14
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hair cycle-dependent basal cell carcinoma tumorigenesis in Ptc1neo67/+ mice exposed to radiation.
  • We examined the effects of hair cycle phase on basal cell carcinoma (BCC) tumorigenesis induced by radiation in mice lacking one Patched allele (Ptc1(neo67/+)).
  • Our results show that Ptc1(neo67/+) mouse skin irradiated in early anagen is highly susceptible to tumor induction, as a 3.2-fold incidence of visible BCC-like tumors was observed in anagen-irradiated compared with telogen-irradiated mice.
  • In fact, in addition to typical BCC-like tumors, we observed development of a distinct basal cell tumor subtype characterized by anti-cytokeratin 14 and anti-smooth muscle actin reactivity.
  • In contrast, there are strong indications for the derivation of typical, smooth muscle actin-negative BCC-like tumors from cell progenitors of interfollicular epidermis.
  • These results underscore the role of follicular bulge stem cells and their progeny with high self-renewal capacity in the formation of basal cell tumors and contribute to clarify the relationship between target cell and tumor phenotype in BCC tumorigenesis induced by radiation.
  • [MeSH-major] Carcinoma, Basal Cell / etiology. Hair Follicle / radiation effects. Neoplasms, Radiation-Induced / etiology. Receptors, Cell Surface / genetics. Skin Neoplasms / etiology
  • [MeSH-minor] Allelic Imbalance. Animals. Cell Lineage. Female. Kruppel-Like Transcription Factors / biosynthesis. Kruppel-Like Transcription Factors / genetics. Loss of Heterozygosity. Male. Mice. Skin / radiation effects. Stem Cells / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16818633.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gli protein, mouse; 0 / Gli2 protein; 0 / Kruppel-Like Transcription Factors; 0 / Receptors, Cell Surface; 0 / patched receptors
  •  go-up   go-down


2. Vincent-Salomon A, Macgrogan G, Charaffe-Jauffret E, Jacquemier J, Arnould L: [Identification of basal-like carcinomas in clinical practice: "triple zero/BRCA1-like" carcinomas]. Bull Cancer; 2010 Mar;97(3):357-63
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Identification of basal-like carcinomas in clinical practice: "triple zero/BRCA1-like" carcinomas].
  • [Transliterated title] Identification en pratique clinique des carcinomes basal-like du sein : des carcinomes "triple zéro/BRCA1-like".
  • Basal-like carcinomas represent 10 to 15% of invasive breast carcinomas and have been identified from gene expression studies.
  • They share a high degree of similarity at the morphological, phenotypical and molecular level with BRCA1 tumors that justify the proposal of a different name such as "triple zero/BRCA1 like" carcinomas for sporadic basal-like carcinomas.
  • Indeed, the current "basal-like" name could suggest a myoepithelial cellular origin of such lesions.
  • Furthermore, tumors with such a basal-like immunophenotype constitute a heterogeneous group of tumors encompassing good prognosis tumors such as adenoid cystic and juvenile secretory carcinomas.
  • There is an urgent need for more specific therapies for basal-like/triple zero/BRCA1-like tumors.
  • Indeed, recent clinical trials with PARP inhibitors for basal-like/BRCA1 like tumors should improve the prognosis of these patients and are a direct benefit of a better understanding of the molecular biology of these tumors.
  • [MeSH-major] Breast Neoplasms / genetics. Carcinoma, Basal Cell / genetics. Gene Expression Profiling / methods. Genes, BRCA1
  • [MeSH-minor] BRCA1 Protein / genetics. BRCA1 Protein / metabolism. Biomarkers, Tumor. Female. Gene Silencing. Genes, p53 / genetics. Humans. Mutation / genetics. Neoplasm Proteins / genetics. Neoplasm Proteins / metabolism. Phenotype. Prognosis. Terminology as Topic


3. Von Hoff DD, LoRusso PM, Rudin CM, Reddy JC, Yauch RL, Tibes R, Weiss GJ, Borad MJ, Hann CL, Brahmer JR, Mackey HM, Lum BL, Darbonne WC, Marsters JC Jr, de Sauvage FJ, Low JA: Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med; 2009 Sep 17;361(12):1164-72
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of the hedgehog pathway in advanced basal-cell carcinoma.
  • BACKGROUND: Mutations in hedgehog pathway genes, primarily genes encoding patched homologue 1 (PTCH1) and smoothened homologue (SMO), occur in basal-cell carcinoma.
  • In a phase 1 clinical trial, we assessed the safety and pharmacokinetics of GDC-0449, a small-molecule inhibitor of SMO, and responses of metastatic or locally advanced basal-cell carcinoma to the drug.
  • METHODS: We selected 33 patients with metastatic or locally advanced basal-cell carcinoma to receive oral GDC-0449 at one of three doses; 17 patients received 150 mg per day, 15 patients received 270 mg per day, and 1 patient received 540 mg per day.
  • We assessed tumor responses with the use of Response Evaluation Criteria in Solid Tumors (RECIST), physical examination, or both.
  • The other 15 patients had either stable disease (11 patients) or progressive disease (4 patients).
  • CONCLUSIONS: GDC-0449, an orally active small molecule that targets the hedgehog pathway, appears to have antitumor activity in locally advanced or metastatic basal-cell carcinoma. (ClinicalTrials.gov number, NCT00607724. )
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Benzimidazoles / administration & dosage. Carcinoma, Basal Cell / drug therapy. Hedgehog Proteins / antagonists & inhibitors. Skin Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anilides. Dose-Response Relationship, Drug. Female. Gene Expression. Humans. Male. Middle Aged. Mutation. Polymerase Chain Reaction. Pyridines. RNA, Messenger / metabolism. Receptors, Cell Surface / genetics. Receptors, Cell Surface / metabolism. Sequence Analysis, DNA. Signal Transduction / drug effects. Transcription Factors / genetics. Transcription Factors / metabolism


Advertisement
4. Jankovic I, Kovacevic P, Visnjic M, Jankovic D, Binic I, Jankovic A: Does incomplete excision of basal cell carcinoma of the eyelid mean tumor recurrence? An Bras Dermatol; 2010 Nov-Dec;85(6):872-7
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does incomplete excision of basal cell carcinoma of the eyelid mean tumor recurrence?
  • INTRODUCTION: Basal cell carcinoma is the most common tumor of the eyelid.
  • OBJECTIVE: To define the relationship between margin clearance at excision and the recurrence rate of basal cell carcinoma of the eyelid.
  • METHODS: This prospective study was conducted with 111 patients submitted to surgery for basal cell carcinoma of the eyelid between 2001 and 2003 and followed up for a period of five years.
  • The patients were evaluated according to age, tumor site, recurrence rate and margin clearance at excision.
  • RESULTS: No significant association was found between incomplete tumor excision and recurrence except in patients under 56 years of age, female patients and in the case of tumors of the medial canthus.
  • CONCLUSION: A risk of recurrence in incompletely excised basal cell carcinomas of the eyelid was only confirmed in younger patients, females and for tumors of the medial canthus.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Eyelid Neoplasms / surgery. Mohs Surgery / methods. Neoplasm Recurrence, Local. Skin Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] An Bras Dermatol. 2011 Mar-Apr;86(2):401; author reply 401-3 [21603839.001]
  • (PMID = 21308312.001).
  • [ISSN] 1806-4841
  • [Journal-full-title] Anais brasileiros de dermatologia
  • [ISO-abbreviation] An Bras Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


5. Longhi P, Serra MP, Robotti E: Incompletely excised basal cell carcinomas: Our guidelines. Onco Targets Ther; 2008;1:1-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incompletely excised basal cell carcinomas: Our guidelines.
  • A retrospective review of 982 patients treated for basal cell carcinoma (BCC) was conducted over a period of 8 years from 1996 to 2004.
  • Two cohorts of patients with involved margin were identified: the group whose basal cell carcinoma was re-excised, and the "wait and see" group.
  • Reexcision is our current practice for incompletely excised tumor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21127747.001).
  • [ISSN] 1178-6930
  • [Journal-full-title] OncoTargets and therapy
  • [ISO-abbreviation] Onco Targets Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC2994206
  • [Keywords] NOTNLM ; basal cell carcinoma / excise / guidelines / tumor
  •  go-up   go-down


6. Ji J, Kump E, Wernli M, Erb P: Gene silencing of transcription factor Gli2 inhibits basal cell carcinomalike tumor growth in vivo. Int J Cancer; 2008 Jan 1;122(1):50-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene silencing of transcription factor Gli2 inhibits basal cell carcinomalike tumor growth in vivo.
  • Basal cell carcinoma (BCC) belongs worldwide to the most frequent malignancy among Caucasians.
  • Therefore, we used a mouse tumor allograft model to investigate the role of Gli2 in tumor formation.
  • A constitutively Gli2 expressing mouse tumor cell line was stably transfected with Gli2-specific shRNA to induce Gli2 gene silencing or with control shRNA.
  • Injecting the Gli2 gene silenced cells into nude mice for tumor formation we detected a strongly retarded tumor growth compared with control tumor cells.
  • Investigating the mechanisms, we found that Gli2 gene silencing has led to the disruption of the tumor structure as demonstrated by staining tumor sections with hematoxylin.
  • Two main reasons for the tumor destruction were identified.
  • Thus, important functions of the transcription factor Gli2 in this tumor model are the prevention of apoptosis and the promotion of microvascularization.
  • [MeSH-major] Carcinoma, Basal Cell / genetics. Gene Silencing. Kruppel-Like Transcription Factors / genetics. Skin Neoplasms / genetics
  • [MeSH-minor] Animals. Apoptosis. HeLa Cells. Humans. In Situ Hybridization. In Situ Nick-End Labeling. Male. Mice. Mice, Nude. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2007 Wiley-Liss, Inc.
  • (PMID = 17721996.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gli2 protein; 0 / Kruppel-Like Transcription Factors
  •  go-up   go-down


7. Wang CH, Hsu TR, Yang TY, Wong TT, Chang FC, Ho DM, Chiang KL, Chang KP: Primary yolk sac tumor of bilateral basal ganglia. J Chin Med Assoc; 2010 Aug;73(8):444-8
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary yolk sac tumor of bilateral basal ganglia.
  • A primary intracranial yolk sac tumor (YST) is a type of germ cell tumor (GCT) and usually involves the pineal or suprasellar regions, as do other GCTs.
  • Primary YST in the basal ganglia is not common, and bilateral basal ganglia involvement is even rarer.
  • Early diagnosis is often difficult because of minimal or subtle findings without space-occupying lesions shown on neuroimaging during the early course of the disease.
  • We report a case of primary intracranial YST encountered in the basal ganglia bilaterally and describe the clinical presentation, diagnostic problem, imaging characteristics, histopathologic features, and prognosis of the tumor.
  • To the best of our knowledge, this is only the third reported case of primary YST confined to the basal ganglia in the literature.
  • [MeSH-major] Basal Ganglia / pathology. Brain Neoplasms / pathology. Endodermal Sinus Tumor / pathology

  • Genetic Alliance. consumer health - Yolk sac tumor.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier. Published by Elsevier B.V. All rights reserved.
  • (PMID = 20728859.001).
  • [ISSN] 1728-7731
  • [Journal-full-title] Journal of the Chinese Medical Association : JCMA
  • [ISO-abbreviation] J Chin Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


8. Blázquez-Sánchez N, de Troya-Martín M, Frieyro-Elicegui M, Fúnez-Liébana R, Martín-Márquez L, Rivas-Ruiz F: Cost Analysis of Mohs Micrographic Surgery in High-Risk Facial Basal Cell Carcinoma. Actas Dermosifiliogr; 2010 Sep;101(7):622-628

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cost Analysis of Mohs Micrographic Surgery in High-Risk Facial Basal Cell Carcinoma.
  • [Transliterated title] Análisis de costes de la cirugía micrográfica de Mohs en el carcinoma basocelular facial de alto riesgo.
  • INTRODUCTION: Mohs micrographic surgery (MMS) is the treatment of choice for high-risk facial basal cell carcinoma (BCC) as it offers the greatest chance of cure with maximum preservation of healthy tissue.
  • Differences were analyzed according to tumor site and size, histologic subtype, and recurrence.
  • The most common tumor site was the nose (57%) followed by the orbital region (25%).
  • Tumor-free margins were achieved in all patients, with no more than 2 stages required in 88% of the cases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2009 Elsevier España, S.L. y AEDV. All rights reserved.
  • (PMID = 28709544.001).
  • [ISSN] 1578-2190
  • [Journal-full-title] Actas dermo-sifiliograficas
  • [ISO-abbreviation] Actas Dermosifiliogr
  • [Language] eng; spa
  • [Publication-type] Journal Article
  • [Publication-country] Spain
  • [Keywords] NOTNLM ; Análisis de costes / Cirugía micrográfica / Cost analysis / Cost-effectiveness / Coste/beneficio / Micrographic surgery / Mohs
  •  go-up   go-down


9. Paavilainen V, Tuominen J, Aho VV, Saari KM: Long-term results after treatment of basal cell carcinoma of the eyelid in South-Western Finland. Eur J Ophthalmol; 2007 Jul-Aug;17:494-500

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results after treatment of basal cell carcinoma of the eyelid in South-Western Finland.
  • : . PURPOSE: Basal cell carcinoma (BCC) is the most common skin cancer of the eyelid, showing an increasing incidence in the white population.
  • RESULTS: The 191 patients had altogether 194 BCC tumors of the eyelid with the mean diameter of the tumor being smaller than 10 mm in 77.3% of cases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28221540.001).
  • [ISSN] 1724-6016
  • [Journal-full-title] European journal of ophthalmology
  • [ISO-abbreviation] Eur J Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


10. Rudolph J, Berl J, Hamm B, Klingebiel R: Magnetic resonance imaging findings of basal cell adenoma in Curschmann-Steinert myotonic dystrophy. Acta Radiol; 2006 Mar;47(2):205-7
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnetic resonance imaging findings of basal cell adenoma in Curschmann-Steinert myotonic dystrophy.
  • We present the magnetic resonance imaging in the unusual combination of a patient with known myotonic dystrophy and recurrent basal cell tumor.
  • [MeSH-major] Adenoma / diagnosis. Carcinoma, Basal Cell / diagnosis. Head and Neck Neoplasms / diagnosis. Magnetic Resonance Imaging. Myotonic Dystrophy / pathology

  • Genetic Alliance. consumer health - Myotonic dystrophy.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16604969.001).
  • [ISSN] 0284-1851
  • [Journal-full-title] Acta radiologica (Stockholm, Sweden : 1987)
  • [ISO-abbreviation] Acta Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Sweden
  •  go-up   go-down


11. Evke E, Minbay FZ, Temel SG, Kahveci Z: Immunohistochemical detection of p53 protein in basal cell skin cancer after microwave-assisted antigen retrieval. J Mol Histol; 2009 Feb;40(1):13-21
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical detection of p53 protein in basal cell skin cancer after microwave-assisted antigen retrieval.
  • p53 is the most frequently altered tumor-suppressor gene in skin cancer.
  • In contrast, the mutant p53 protein has an extended half-life in tumor cells and can be detected by immunohistochemical methods. p53 is widely used as an indicator of tumor aggression and progression.
  • This study was designed to evaluate the efficacy of different fixatives, of microwaving and microwave pretreatment method to retrieve p53 immunoreactivity in paraffin-embedded non-lesioned (adjacent normal tissue) human skin samples or pathological human skin samples diagnosed as basal cell carcinoma.
  • In this study the effects of six different fixation methods on the immunohistochemical staining have been investigated in basal cell tumor specimens.
  • [MeSH-major] Carcinoma, Basal Cell / metabolism. Immunohistochemistry / methods. Microwaves. Skin Neoplasms / metabolism. Tumor Suppressor Protein p53 / analysis

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. FORMALDEHYDE .
  • Hazardous Substances Data Bank. ETHANOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1995 Nov 30;333(22):1507-8 [7477163.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 May 9;92(10):4407-11 [7753819.001]
  • [Cites] Histochem J. 1988 Jun-Jul;20(6-7):323-8 [3065303.001]
  • [Cites] Int J Cancer. 1990 Nov 15;46(5):839-44 [2228312.001]
  • [Cites] Biotech Histochem. 2005 May-Aug;80(3-4):123-32 [16298897.001]
  • [Cites] Acta Histochem. 2006;107(6):421-34 [16256175.001]
  • [Cites] J Neurosci Methods. 1994 Dec;55(2):183-90 [7723382.001]
  • [Cites] Oncogene. 1991 Oct;6(10):1785-9 [1717923.001]
  • [Cites] J Microsc. 2000 Jan;197(Pt 1):101-6 [10620153.001]
  • [Cites] Methods Mol Biol. 2003;234:231-43 [12824536.001]
  • [Cites] Nature. 1997 May 15;387(6630):299-303 [9153396.001]
  • [Cites] Biotech Histochem. 2006 Mar-Jun;81(2-3):63-9 [16908430.001]
  • [Cites] Br J Dermatol. 1993 Mar;128(3):237-41 [8471506.001]
  • [Cites] Micron. 1994;25(2):151-70 [8055246.001]
  • [Cites] Eur J Dermatol. 2006 Sep-Oct;16(5):543-7 [17101476.001]
  • [Cites] Am J Clin Pathol. 1994 Nov;102(5):665-70 [7942634.001]
  • [Cites] Nature. 1997 May 15;387(6630):296-9 [9153395.001]
  • [Cites] Am J Clin Pathol. 1994 Feb;101(2):177-80 [8116572.001]
  • [Cites] Histochem J. 1988 Jun-Jul;20(6-7):313-22 [2464564.001]
  • [Cites] J Neurosci Methods. 2006 Sep 30;156(1-2):154-60 [16621014.001]
  • [Cites] Cancer Res. 1996 Jun 1;56(11):2649-54 [8653711.001]
  • [Cites] Scanning. 1993 Mar-Apr;15(2):88-98 [8287207.001]
  • [Cites] Biotech Histochem. 2001 Sep-Nov;76(5-6):233-7 [11871743.001]
  • [Cites] Mod Pathol. 2000 Mar;13(3):217-22 [10757331.001]
  • [Cites] Br Med Bull. 1997;53(3):522-38 [9374035.001]
  • [Cites] Biotech Histochem. 1997 May;72(3):144-7 [9187737.001]
  • [Cites] Am J Pathol. 1993 Nov;143(5):1389-97 [7901994.001]
  • [Cites] EMBO J. 1999 Mar 15;18(6):1660-72 [10075936.001]
  • [Cites] Histochem J. 1988 Jun-Jul;20(6-7):373-87 [2464568.001]
  • [Cites] J Microsc. 1998 Nov;192(Pt 2):212-6 [9853377.001]
  • [Cites] Biotech Histochem. 2003 Apr;78(2):119-28 [14533848.001]
  • [Cites] J Histochem Cytochem. 1991 Jun;39(6):741-8 [1709656.001]
  • [Cites] Eur J Morphol. 2001 Dec;39(5):313-7 [12221513.001]
  • [Cites] Histopathology. 1993 Jan;22(1):45-50 [8436341.001]
  • [Cites] Am J Clin Pathol. 1992 Feb;97(2):244-9 [1546693.001]
  • [Cites] FASEB J. 2002 Mar;16(3):420-2 [11790725.001]
  • [Cites] J Histochem Cytochem. 1997 Mar;45(3):327-43 [9071315.001]
  • (PMID = 19096907.001).
  • [ISSN] 1567-2387
  • [Journal-full-title] Journal of molecular histology
  • [ISO-abbreviation] J. Mol. Histol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53; 1HG84L3525 / Formaldehyde; 3K9958V90M / Ethanol
  •  go-up   go-down


12. Hewes CA, Sullins KE: Use of cisplatin-containing biodegradable beads for treatment of cutaneous neoplasia in equidae: 59 cases (2000-2004). J Am Vet Med Assoc; 2006 Nov 15;229(10):1617-22
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of cisplatin-containing biodegradable beads for treatment of cutaneous neoplasia in equidae: 59 cases (2000-2004).
  • OBJECTIVE: To determine outcome for equids with cutaneous neoplasms treated with cisplatin-containing biodegradable beads, alone or in conjunction with debulking.
  • RESULTS: 22 tumors were sarcoids, 6 were fibrosarcomas, 1 was a fibroma, 2 were peripheral nerve sheath tumors, 11 were squamous cell carcinomas, 14 were melanomas (13 gray horses and 1 bay horse), 1 was a lymphosarcoma, 1 was an adenocarcinoma, and 1 was a basal cell tumor.
  • Forty-five (76%) animals underwent conventional or laser debulking of the tumor prior to bead implantation.
  • This included 20 of 22 animals with spindle cell tumors (including 11/13 horses with sarcoids), 6 of 10 animals with squamous cell carcinomas, 13 of 14 animals with melanomas, and 2 of 3 animals with other tumor types.
  • CONCLUSIONS AND CLINICAL RELEVANCE: Results suggest that implantation of cisplatin-containing biodegradable beads, with or without tumor debulking, may be an effective treatment for equidae with various cutaneous neoplasms.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Equidae. Horse Diseases / drug therapy. Skin Neoplasms / veterinary
  • [MeSH-minor] Animals. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / surgery. Carcinoma, Squamous Cell / veterinary. Female. Horses. Laser Therapy / methods. Laser Therapy / veterinary. Male. Melanoma / drug therapy. Melanoma / surgery. Melanoma / veterinary. Retrospective Studies. Sarcoma / drug therapy. Sarcoma / surgery. Sarcoma / veterinary. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17107319.001).
  • [ISSN] 0003-1488
  • [Journal-full-title] Journal of the American Veterinary Medical Association
  • [ISO-abbreviation] J. Am. Vet. Med. Assoc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


13. Bohn AA, Wills T, Caplazi P: Basal cell tumor or cutaneous basilar epithelial neoplasm? Rethinking the cytologic diagnosis of basal cell tumors. Vet Clin Pathol; 2006 Dec;35(4):449-53
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell tumor or cutaneous basilar epithelial neoplasm? Rethinking the cytologic diagnosis of basal cell tumors.
  • The cytologic interpretation was malignant neoplasia with histiocytic inflammation.
  • Differentials included a carcinoma or, given the melanin pigment and variable morphology of the cells, possibly malignant melanoma.
  • Histologically, the tumor was diagnosed as a basal cell epithelioma.
  • Neoplasms that once were lumped into the broad histologic diagnosis of basal cell tumors have since been split into distinct entities, dependent on evidence of differentiation into epidermis, trichofollicular epithelium, or sweat or sebaceous glands.
  • Although histologic reclassification has resulted in removal of most of these entities from the original basal cell tumor category, a cytologic diagnosis of basal cell tumor continues to be used to represent the large, heterogeneous group of epidermal, trichofollicular, and adnexal skin tumors with basal cell characteristics.
  • The case in this report demonstrates the heterogeneity of neoplasms that may be diagnosed cytologically as basal cell tumors and supports the need for cytologic criteria and nomenclature that better reflect potential variation in tissue differentiation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17123253.001).
  • [ISSN] 0275-6382
  • [Journal-full-title] Veterinary clinical pathology
  • [ISO-abbreviation] Vet Clin Pathol
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Schulz H: [Pigmented lesion on the temple. Pigment cell tumor, basal cell carcinoma, or irritated seborrheic keratosis?]. Hautarzt; 2010 Dec;61(12):1061-2
Genetic Alliance. consumer health - Keratosis, seborrheic.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pigmented lesion on the temple. Pigment cell tumor, basal cell carcinoma, or irritated seborrheic keratosis?].
  • [Transliterated title] Pigmentierte Läsion der Schläfenregion. Melanozytärer Tumor, Basalzellkarzinom oder irritierte seborrhoische Keratose?
  • The slightly raised skin tumor with well-defined margins had appeared 3 years earlier, slowly enlarging and finally changing in color.
  • Biopsy of the tumor demonstrated hyperplasia of the epidermis and normal basaloid keratinocytes partially extending into the dermis.
  • [MeSH-major] Carcinoma, Basal Cell / diagnosis. Facial Dermatoses / diagnosis. Facial Neoplasms / diagnosis. Keratosis, Seborrheic / diagnosis. Nevus, Pigmented / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dermatol Clin. 2001 Apr;19(2):347-57 [11556243.001]
  • [Cites] Arch Dermatol. 2002 Dec;138(12):1556-60 [12472342.001]
  • (PMID = 21069503.001).
  • [ISSN] 1432-1173
  • [Journal-full-title] Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete
  • [ISO-abbreviation] Hautarzt
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


15. Bornstein MM, Filippi A, Altermatt HJ, Lambrecht JT, Buser D: [The odontogenic keratocyst--odontogenic cyst or benign tumor?]. Schweiz Monatsschr Zahnmed; 2005;115(2):110-28
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The odontogenic keratocyst--odontogenic cyst or benign tumor?].
  • [Transliterated title] Die odontogene Keratozyste--odontogene Zyste oder benigner Tumor?
  • Multiple odontogenic keratocysts are a well-recognized feature of the nevoid basal cell carcinoma syndrome.
  • This led to the tentative suggestion that the keratocyst might be a benign cystic neoplasm rather than simply an odontogenic cyst.

  • MedlinePlus Health Information. consumer health - Jaw Injuries and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15771334.001).
  • [ISSN] 0256-2855
  • [Journal-full-title] Schweizer Monatsschrift fur Zahnmedizin = Revue mensuelle suisse d'odonto-stomatologie = Rivista mensile svizzera di odontologia e stomatologia
  • [ISO-abbreviation] Schweiz Monatsschr Zahnmed
  • [Language] FRE; GER
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 68238-35-7 / Keratins
  • [Number-of-references] 69
  •  go-up   go-down


16. Cañadas I, Arumi M, Lema L, Martinez A, Grande E, Bellosillo B, Rojo F, Rovira A, Albanell J, Arriola E: MET in small cell lung carcinoma (SCLC): Effects of a MET inhibitor in SCLC cell lines and prognostic role of MET status in patients. J Clin Oncol; 2009 May 20;27(15_suppl):e14617

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MET in small cell lung carcinoma (SCLC): Effects of a MET inhibitor in SCLC cell lines and prognostic role of MET status in patients.
  • METHODS: Total and p-MET expression (Western Blot), gene copy number (FISH), and exon 14 activating mutations (sequencing) were evaluated in H69 and H69AR SCLC cell lines.
  • PHA-665752 (PHA), alone or combined with doxorubicin, was used to study the effects of pathway inhibition on viability, colony formation and invasion assays in basal/stimulated conditions (HGF).
  • RESULTS: H69 and H69AR (both R988C mutated) expressed MET at basal conditions, but not p-MET.
  • MET expression was found in 98% normal bronchial epithelia, and 78% tumor samples (overexpression 38%).
  • MET expression was associated with improved overall and disease free survival (p: 0.06 and 0.051, respectively).
  • All p-MET positive cases within MET expressing tumors, showed relapsed disease (83% in negative p-MET samples, p=0.065), suggesting MET activation may revert the good prognosis linked to total MET expression.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964125.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Sausville E, Garbo L, Weiss GJ, Anthony S, Shkolny D, Yurkovetskiy AV, Bethune C, Fram RJ: A phase I study of the safety and pharmacokinetics (PK) of XMT-1001 given as an intravenous (IV) infusion once every three weeks to patients with advanced solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):2574

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • XMT-1001 demonstrated an improved therapeutic window as compared with CPT and irinotecan in human tumor xenograft models, providing a compelling rationale for its clinical development.
  • Stable disease was observed in 7 pts with the following tumor types and dose levels expressed in mg CPT equivalents/m<sup>2</sup>: NSCLC (1.0 mg/m<sup>2</sup>, 6 wks), ovarian (4.9 mg/m<sup>2</sup>, 12 wks), pancreas (4.9 mg/m<sup>2</sup>, 36 wks), appendiceal (7.3 mg/m<sup>2</sup>, 12 wks), bile duct (9.1 mg/m<sup>2</sup>, 18 wks), basal cell (11.6 mg/m<sup>2</sup>, 6 wks), and colon (15.4 mg/m<sup>2</sup>, 6 wks).
  • Prolonged stable disease was observed in patients with refractory tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961894.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Hanker LC, Karn T, Rody A, Ruckhäberle E, Solbach C, Kaufmann M: Prognostic value of gene expression of p63 by microarray analysis in estrogen receptor positive and negative breast cancer. J Clin Oncol; 2009 May 20;27(15_suppl):566

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This gene family seems to play an important role in carcinogenesis and its members may act as oncogenes or tumor suppressor genes.
  • P63 was found to be overexpressed in a subset of highly aggressive breast cancers that represent a basal and myoepithelial phenotype and have a poor clinical outcome.
  • This protein seems to be a specific myoepithelial cell marker in normal breast tissue and might represent a prognostic factor in breast cancer.
  • RESULTS: P63 expression showed a strong correlation with patient's age (χ<sup>2</sup>-test, p < 0.001), tumor size (p < 0.003), proliferation rate (p < 0.001), Topo2α expression (p = 0.001) and estrogen receptor expression (p = 0.017).
  • In univariate Cox regression analysis p63 showed a hazard ratio (HR) of 1.61 (95% CI 1.31-2.00, p < 0.001) for disease free survival.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960724.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. DeMichele A, Dunn L, Gimotty P, Livasy C, Perou C, Carey L, Esserman L: Loss of p27 expression and response to neoadjuvant chemotherapy: Results from the I-SPY Trial (CALGB150007/150012, ACRIN6657). J Clin Oncol; 2009 May 20;27(15_suppl):11091

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The I-SPY Trial is a multicenter study of locally advanced breast cancer in which pretreatment tumor biopsies were obtained prior to the administration of anthracycline and taxane-based neoadjuvant therapy, and serial MRIs were performed to assess response to treatment.
  • The aim of this study was to determine if loss of tumor p27 expression was associated with response to cytotoxic therapy.
  • Immunohistochemistry for p27 was performed centrally on pretreatment core samples using rabbit anti-p27 (Upstate Cell Signaling #06-445).
  • Compared to normal p27 expression, absent p27 was significantly associated with ER negativity (48% vs. 14%; p=0.03), PR negativity (59% vs. 21%; p=0.03), Her2 overexpression (28% vs. 14%; p=0.017) and basal molecular subtype (29% vs. 13%).
  • Low or absent p27 was not associated with response to therapy as measured by pCR, RCB or change in tumor diameter by MRI.
  • CONCLUSIONS: p27 loss in this neoadjuvant patient population was associated with aggressive tumor features, but not predictive of response to cytotoxic therapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963119.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Kennecke HF, Voduc D, Leung S, Cryns VL, Perou CM, Nielsen TO, Cheang M: α-basic-crystallin expression in basal-like breast cancer and its association with brain metastasis. J Clin Oncol; 2009 May 20;27(15_suppl):1025

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] α-basic-crystallin expression in basal-like breast cancer and its association with brain metastasis.
  • : 1025 Background: Basal-like breast cancers are high grade tumors with poor prognosis, having propensity for brain and lung metastasis (Perou et al.
  • α-basic-crystallin (αBC), a small heat shock protein with anti-apoptotic and oncogenic activity, is expressed in about half of basal-like breast cancers but only 6% of other types (Moyano et al.
  • Among patients who developed distant metastatic disease, the 10-yr BCSS survival in αBC+ and - tumors was 12% and 29%.
  • Sites of metastatic disease included: brain (15%), lung (35%), liver (35%) and bone (65%).
  • Basal-like tumors with brain metastasis commonly co-expressed αBC (Chi-square p=0.006).
  • CONCLUSION: αBC is significantly associated with brain metastasis, particularly among basal breast cancers.
  • These findings suggested that αBC may be involved in tumor cell metastasis and may allow early identification of a subset of patients at particularly high risk of brain metastasis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961038.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Iwase H, Yamamoto Y, Kurebayashi J, Tsuda H, Ota T, Kurosumi M, Miyamoto K, Iwase T, Research Group of the Japanese Breast Cancer Society: Clinicopathologic and prognostic features of triple-negative breast cancer analyzed in registration data of the Japanese Breast Cancer Society, 11705 cases. J Clin Oncol; 2009 May 20;27(15_suppl):e22122

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Squamous cell, spindle cell carcinoma, or metaplastic carcinoma with bone/cartilage metaplasia was found in only TN type.
  • Pathological response rate of NAC, including grade 2 and 3, was higher in TN tumor as 51.5 % (22/53) than in Luminal A tumor as 16.7% (12/72).
  • Central reviews of immunohistochemistry, such as ER, PgR, HER2, CK5/6, EGFR etc, will be confirmed in this cohort, for TN tumors are similar to basal-like tumors discriminated by gene- profiling.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963560.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Ascierto PA, Napolitano M, Celentano E, Simeone E, Gentilcore G, Capone M, Ciccarelli L, Palmieri G, Castello G, Mozzillo N: Reduction of circulating regulatory T cell (Treg) by intravenous high-dose interferon (HDI) treatment in melanoma patients. J Clin Oncol; 2009 May 20;27(15_suppl):9040

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduction of circulating regulatory T cell (Treg) by intravenous high-dose interferon (HDI) treatment in melanoma patients.
  • : 9040 Background: T regulatory (Treg) cells are an immunoregulatory cell type which express high levels of surface CD25, CTLA-4, and GITR.
  • Tregs have been shown to be present in tumor and tumor-draining lymph nodes, acting as an inhibitory population blocking effector cell function.
  • Moreover, it has been observed great differences between the disease status, the prognosis (recurred/not recurred pts, alive/deceased) and an increased basal percentage of cTreg.
  • Our preliminary data are consistent for an effect of HDI on reducing cTreg, although no conclusion about the role of such reduction in terms of response to treatment or as prognostic markers of better/worse disease can be inferred.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962106.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Fury MG, Sherman E, Stambuk H, Haque S, Lisa D, Shen R, Carlson D, Pfister DG: Phase I study of everolimus (E; RAD001) + low-dose weekly cisplatin (C) for patients with advanced solid tumors: Preliminary results. J Clin Oncol; 2009 May 20;27(15_suppl):e14527

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e14527 Background: Preclinical studies demonstrate synergistic anti-tumor activity with the combination of E + C.
  • At DL1, 3 patients were inevaluable (1 withdrawal of consent prior to treatment, 1 disease progression during cycle 1, 1 recurrent diverticulitis during cycle 1) and were replaced.
  • At DL2, one patient experienced grade 3 small bowel obstruction of uncertain etiology, and the dose level was expanded to 6 evaluable patients without additional DLT.
  • Minor response seen in pulmonary carcinoid (n = 1); prolonged SD ≥ 6 cycles seen in pulmonary carcinoid (n=2), basal cell carcinoma (n=1), and esthesioneuroblastoma (n=1).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963576.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Prat A, Karginova O, Fan C, Perou CM: Notch-associated expression profiles in basal-like and claudin-low breast cancer molecular subtypes. J Clin Oncol; 2009 May 20;27(15_suppl):11017

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Notch-associated expression profiles in basal-like and claudin-low breast cancer molecular subtypes.
  • : 11017 Background: An attractive candidate target for breast cancer (BC) and BC tumor-initiating cells is the Notch signaling pathway.
  • METHODS: Breast basal-like, luminal and HER2+ cell lines were examined for sensitivity to gamma-secretase inhibition (GSI).
  • Gene expression data from the most sensitive cell line was analyzed during treatment and upon releasing from GSI (4h, 8h and 24h post-treatment).
  • This Notch-associated signature identified in vitro was used to classify 2 distinct sporadic breast tumor populations (UNC and NKI, n=495).
  • Each tumor sample was categorized into 6 molecular subtypes (basal-like, claudin-low [submitted], luminal A/B, HER2-enriched and normal-like).
  • RESULTS: In vitro, breast basal-like cell lines SUM102 and SUM149 were more sensitive to GSI (IC50, 0.3 and 1.5μM, respectively) compared to the luminal MCF7 (>10μM) and HER2+ SKBR3 (>5μM) cell lines.
  • Selected GO terms overrepresented in this signature were the following (EASE score, p<0.01): Wnt and Hedgehog signaling, embryonic development and cell differentiation.
  • This Notch-associated poor prognostic signature was highly expressed in >90% of basal-like tumors.
  • The second cluster was highly expressed in the recently identified claudin-low subtype, and was uniquely enriched with genes involved in cell differentiation (Sox7/9, Hey2, Dll1, Fzd5) and cell adhesion.
  • CONCLUSIONS: Notch associated expression profiles are associated with basal-like and claudin-low BC subtypes, providing additional biological insight of pathway activation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963972.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Guerrero-Zotano A Sr, Gavila J, Climent MA, Juan MJ, Guillem V, Ruiz A: Response to neoadjuvant chemotherapy and outcome based on breast cancer subtype. J Clin Oncol; 2009 May 20;27(15_suppl):e11516

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We used immunohistochemistry surrogate markers to classify tumors according to known breast cancer subtypes and examined the relationship between neoadjuvant chemotherapy (NAC) response and long-term end points, including distant disease-free survival (DDFS) and overall survival (OS).
  • Breast cancer subtypes were defined as follows: Luminal A: Estrogen receptor positive (ER+) and/or progesterone peceptor positive (PR+), human epidermal growth factor receptor 2-positive (Her-2+); Luminal B: ER+ and/or PR+,Her-2+; Basal: ER-,PR-,Her-2-;HER2: ER-,PR-,Her-2 +.
  • ER and PR positive scored as positive if tumor cell nuclear staining was at least 2+.
  • RESULTS: 121 (45.8%) patients were classifed as Luminal A; 22 (8.1%) as Luminal B; 75 (27.7%) as Basal, and 50 (18.5%) as HER2.
  • Among patients who didn´t achieved pathologic complete response (pCR), basal and HER2 subtypes have the worst outcome (4 years SG 80% and 72% respectevely) compared with Luminal A (4 years SG: 94.7%), (log-rank p=0.009).
  • CONCLUSIONS: Basal and HER2 tumor despite high chemosensitivity have worst long term outcome, particularly if pCR is not achieved after NAC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964643.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Ono M, Tsuda H, Shimizu C, Yamamoto S, Shibata T, Kouno T, Tamura K, Ando M, Katsumata N, KInoshita T, Fujiwara Y: Evaluation of tumor-infiltrating lymphocytes (TIL) and tumor cell apoptosis as predictive markers for response to neoadjuvant chemotherapy in triple-negative breast cancer. J Clin Oncol; 2009 May 20;27(15_suppl):559

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of tumor-infiltrating lymphocytes (TIL) and tumor cell apoptosis as predictive markers for response to neoadjuvant chemotherapy in triple-negative breast cancer.
  • We examined the value of histological parameters including tumor-infiltrating lymphocytes (TIL) and tumor cell apoptosis as surrogate markers for pCR in TNBC.
  • We first immunohistochemically confirmed TNBC and basal-like subtype by current criteria for ER, PgR, and HER-2, cytokeratin (CK) 5/6, CK14, EGFR, and p53.
  • All cases were TNBC, and 54 tumors (59%) were basal-like subtype defined as expression of at least one of CK5/6, CK14 and EGFR in >1% of cancer cells.
  • These parameters were also examined in resected tumor specimens from 21 non-pCR cases.
  • The pCR rate did not differ significantly between the basal-like type (31%) and non-basal-like type (24%).
  • CONCLUSIONS: TIL and the level of tumor cell apoptosis appeared predictive markers for response to NAC in TNBC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960670.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Xu E, Wang X, Hao Z, Chen Z, Lu X: Germinoma in the basal ganglia with an abnormal karyotype: case report and review of the literature. Childs Nerv Syst; 2010 May;26(5):707-12
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Germinoma in the basal ganglia with an abnormal karyotype: case report and review of the literature.
  • INTRODUCTION: Germ cell tumor of basal ganglia with abnormal constitutional karyotype has been rarely reported.
  • Magnetic resonance imaging showed high intensity on T1-weighted, T2-weighted, and contrast-enhanced T1-weighted images in the left basal ganglia and ipsilateral cerebral hemiatrophy predominantly in the basal ganglia and midbrain.
  • Germinoma in the left basal ganglia was confirmed by stereotactic biopsy and immunochemical examination.
  • His constitutional karyotype was 46, XY, t (8; 19), (p23.1; p13.1), a novel chromosomal abnormality.
  • DISCUSSION: Intracranial germinoma, a potentially curable tumor, should be considered in children with nonspecific neurological symptoms, endocrinologic changes, and ipsilateral cerebral hemiatrophy on computed tomography or magnetic resonance.
  • Investigation of chromosomal aberrations in those patients would clarify the tumorigenesis and lead to possibilities for novel disease-specific therapies.
  • [MeSH-major] Basal Ganglia Diseases / genetics. Brain Neoplasms / genetics. Germinoma / genetics

  • Genetic Alliance. consumer health - Germinoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1993 Apr 1;71(7):2306-11 [8453551.001]
  • [Cites] Mod Pathol. 2006 Jun;19(6):864-73 [16607373.001]
  • [Cites] Hum Genet. 1995 Dec;96(6):644-50 [8522320.001]
  • [Cites] Pediatr Neurosurg. 2000 Nov;33(5):261-264 [11155064.001]
  • [Cites] Surg Neurol. 1997 Jan;47(1):28-31 [8986161.001]
  • [Cites] Neuroradiology. 1998 Aug;40(8):507-11 [9763338.001]
  • [Cites] J Pathol. 1999 Nov;189(3):387-93 [10547601.001]
  • [Cites] Pediatr Radiol. 2006 Apr;36(4):325-30 [16463029.001]
  • [Cites] Childs Nerv Syst. 1997 Oct;13(10):563-6 [9403208.001]
  • [Cites] Cancer Genet Cytogenet. 1996 Mar;87(1):29-33 [8646736.001]
  • [Cites] AJNR Am J Neuroradiol. 1983 May-Jun;4(3):478-80 [6410776.001]
  • [Cites] Otolaryngol Head Neck Surg. 2003 Dec;129(6):698-704 [14663438.001]
  • [Cites] Childs Nerv Syst. 2006 Dec;22(12):1513-8 [17053934.001]
  • [Cites] J Neurosurg Pediatr. 2008 Aug;2(2):118-24 [18671616.001]
  • [Cites] Pediatr Blood Cancer. 2008 Jan;50(1):177-9 [16700048.001]
  • [Cites] Pediatr Neurosurg. 2004 Nov-Dec;40(6):306-11 [15821363.001]
  • [Cites] Genes Chromosomes Cancer. 2000 Mar;27(3):244-51 [10679913.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Jul 1;62(3):803-8 [15936563.001]
  • [Cites] Am J Pathol. 2000 Aug;157(2):579-86 [10934160.001]
  • [Cites] Oncology (Williston Park). 2005 May;19(6):705-11; discussion 711-2, 715-7, 721 [15971448.001]
  • [Cites] J Neurosurg. 2005 May;102(5):897-901 [15926716.001]
  • [Cites] Arch Neurol. 1991 Jun;48(6):652-7 [2039390.001]
  • [Cites] Surg Neurol. 2000 May;53(5):432-7; discussion 437-8 [10874141.001]
  • [Cites] AJNR Am J Neuroradiol. 2006 Jun-Jul;27(6):1204-10 [16775265.001]
  • [Cites] World J Gastroenterol. 2007 Feb 21;13(7):1090-7 [17373745.001]
  • [Cites] Blood. 2001 Dec 1;98(12):3479-82 [11719392.001]
  • [Cites] Acta Neurochir (Wien). 2002 Feb;144(2):145-50; discussion 150 [11862514.001]
  • [Cites] Cancer. 1998 May 1;82(9):1749-55 [9576298.001]
  • [Cites] Acta Pathol Jpn. 1986 Jan;36(1):143-9 [3962671.001]
  • [Cites] J Neurooncol. 2003 Feb;61(3):215-8 [12675314.001]
  • [Cites] Neuroradiology. 2002 May;44(5):389-94 [12012122.001]
  • [Cites] Neurol Med Chir (Tokyo). 1992 Mar;32(3):163-5 [1377800.001]
  • [Cites] J Pathol. 2000 Jun;191(2):187-92 [10861580.001]
  • [Cites] Nat Rev Cancer. 2005 Mar;5(3):210-22 [15738984.001]
  • [Cites] AJNR Am J Neuroradiol. 2005 May;26(5):1166-9 [15891178.001]
  • [Cites] Childs Nerv Syst. 1990 Jan;6(1):3-7 [2178773.001]
  • [Cites] J Neurooncol. 2009 Mar;92(1):37-44 [18953691.001]
  • [Cites] Pediatr Neurosurg. 1998 Oct;29(4):199-202 [9876249.001]
  • [Cites] J Neuropathol Exp Neurol. 2000 Sep;59(9):815-21 [11005262.001]
  • (PMID = 19876633.001).
  • [ISSN] 1433-0350
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 39
  •  go-up   go-down


28. Allali J, D'Hermies F, Renard G: Basal cell carcinomas of the eyelids. Ophthalmologica; 2005 Mar-Apr;219(2):57-71

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinomas of the eyelids.
  • Basal cell carcinomas (BCC) are the more frequent malignant tumors seen in France as in other western countries.
  • BCC is the most common cause leading to eyelid reconstructive surgery; a surgery which has a triple objective: tumor removal, functionality and an esthetic outcome.
  • [MeSH-major] Carcinoma, Basal Cell. Eyelid Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 S. Karger AG, Basel.
  • (PMID = 15802929.001).
  • [ISSN] 0030-3755
  • [Journal-full-title] Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift für Augenheilkunde
  • [ISO-abbreviation] Ophthalmologica
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 141
  •  go-up   go-down


29. Braun RP, Klumb F, Girard C, Bandon D, Salomon D, Skaria A, Adatto M, French LE, Saurat JH, Vallée JP: Three-dimensional reconstruction of basal cell carcinomas. Dermatol Surg; 2005 May;31(5):562-6; discussion 566-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Three-dimensional reconstruction of basal cell carcinomas.
  • BACKGROUND: Basal cell carcinoma (BCC) is the most common type of skin cancer.
  • One of the main problems with BCC is the risk of local recurrence of the tumor after treatment.
  • OBJECTIVE: To better understand the tumor morphology and growth pattern of BCC, we tried to develop a method that provides a precise three-dimensional model of the tumor.
  • METHODS: Because Mohs surgery provides the best overview of the tumor and the tumor margins (both lateral and in depth), the reconstruction was based on slides from Mohs surgery.
  • After digitization and processing of the slides, the tumor was then surrounded by a Mohs surgeon on a computer screen.
  • These selections (lines) were used for a three-dimensional reconstruction of the tumor using MedSurf3D software.
  • CONCLUSIONS: Three-dimensional reconstruction is a fascinating tool that might improve our understanding of the behavior, growth pattern, and tumor morphology of BCCs.
  • This technique might also be useful in other fields of cutaneous oncology, such as the calculation of the tumor volume of melanomas.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Mohs Surgery / methods. Skin Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15962742.001).
  • [ISSN] 1076-0512
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 24
  •  go-up   go-down


30. Grønbaek K, Guldberg P: [Acquired mutations--basic cancer biology]. Ugeskr Laeger; 2006 Jun 12;168(24):2335-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Erhvervede mutationer--basal cancerbiologi.
  • It is now well-established that cancer is a genetic disease, although in most cases not inherited.
  • A sporadic cancer develops when a somatic cell acquires specific growth advantages through successive accumulation of changes in cancer genes, including oncogenes, tumor suppressor genes and stability genes.
  • Herein, we give a brief overview of the basic genetic changes in cancer and discuss how specific gene alterations may contribute to the development of malignant melanoma.
  • [MeSH-major] Mutation / genetics. Neoplasms / genetics
  • [MeSH-minor] Genes, Tumor Suppressor. Humans. Melanoma / genetics. Models, Genetic. Neoplasm Metastasis / genetics. Oncogenes / genetics. Skin Neoplasms / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16822414.001).
  • [ISSN] 1603-6824
  • [Journal-full-title] Ugeskrift for laeger
  • [ISO-abbreviation] Ugeskr. Laeg.
  • [Language] dan
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


31. Chuprov IN: [Basal-cell carcinoma of the skin]. Arkh Patol; 2007 Nov-Dec;69(6):52-5
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Basal-cell carcinoma of the skin].
  • The paper represents an overview of updated literature concerning common skin neoplasms.
  • The clinical manifestation of the basal cell carcinoma varies significantly according to the patients age, tumor size, localization and duration of the neoplastic process, histological type of the tumor, including proliferative activity and stromal reactions.
  • [MeSH-major] Carcinoma, Basal Cell. Skin Neoplasms
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18290385.001).
  • [ISSN] 0004-1955
  • [Journal-full-title] Arkhiv patologii
  • [ISO-abbreviation] Arkh. Patol.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 53
  •  go-up   go-down


32. Kawata R, Yoshimura K, Lee K, Araki M, Takenaka H, Tsuji M: Basal cell adenoma of the parotid gland: a clinicopathological study of nine cases--basal cell adenoma versus pleomorphic adenoma and Warthin's tumor. Eur Arch Otorhinolaryngol; 2010 May;267(5):779-83
Genetic Alliance. consumer health - Warthin's tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell adenoma of the parotid gland: a clinicopathological study of nine cases--basal cell adenoma versus pleomorphic adenoma and Warthin's tumor.
  • The aim of this study is to investigate the clinical and pathological characteristics of basal cell adenoma (BCA) and to compare the diagnosis/treatment of BCA with those of Warthin's tumor (WT) and pleomorphic adenoma (PA).
  • Among 192 patients with benign tumors of the parotid gland who underwent surgery, 9 had BCA.
  • All of these tumors showed a benign pattern on computed tomography and magnetic resonance imaging.
  • Considering the gender difference, tumor site, and age, it is necessary to differentiate BCA from PA rather than from WT.
  • BCA is the third most common of the benign parotid tumors, following WT and PA, although its incidence is low.
  • When PA and WT are ruled out by FNAB after a tentative diagnosis of benign tumor has been based on imaging findings, BCA should be considered.
  • [MeSH-major] Adenolymphoma / pathology. Adenoma / pathology. Adenoma, Pleomorphic / pathology. Parotid Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Staging. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Diagn Cytopathol. 2007 Feb;35(2):85-90 [17230571.001]
  • [Cites] Acta Otolaryngol. 1998 Jul;118(4):588-93 [9726688.001]
  • [Cites] Arch Klin Exp Ohren Nasen Kehlkopfheilkd. 1967;189(3):302-16 [5595712.001]
  • [Cites] Radiat Med. 2004 Jul-Aug;22(4):260-4 [15468947.001]
  • [Cites] Cancer. 1982 Aug 15;50(4):736-45 [6284339.001]
  • [Cites] Br J Radiol. 2005 Jul;78(931):642-5 [15961849.001]
  • [Cites] Med Oral Patol Oral Cir Bucal. 2006 Mar 01;11(2):E206-9 [16505803.001]
  • [Cites] Cancer. 1998 Feb 1;82(3):439-47 [9452259.001]
  • (PMID = 19908055.001).
  • [ISSN] 1434-4726
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


33. Abenoza P, Kowalczyk J, Nousari CH: Basal cell carcinoma-associated paratumoral follicular and epidermal hyperplasia. Am J Dermatopathol; 2010 Jun;32(4):348-51
MedlinePlus Health Information. consumer health - Skin Conditions.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma-associated paratumoral follicular and epidermal hyperplasia.
  • Reactive epithelial hyperplasia is a well-known phenomenon which occurs adjacent to certain neoplasms such as cutaneous fibrous histiocytoma, granular cell tumor, Spitz nevus, and melanoma.
  • We report 46 cases of paratumoral follicular and epidermal hyperplasia associated with basal cell carcinoma (BCC).
  • It may resemble other tumors such as squamous cell carcinoma and may appear in sections where BCC is absent.
  • The recognition of this entity may help dermatopathologists avoid misdiagnosing this process as a tumor and can suggest further search (section through the block or rebiopsy) when this reactive phenomenon is seen in sections without the associated BCC.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Skin Diseases / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / pathology. Diagnosis, Differential. Female. Humans. Hyperplasia / pathology. Male. Middle Aged. Young Adult

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Dermatopathol. 2011 Feb;33(1):107 [21239900.001]
  • (PMID = 20145534.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Figueroa A, Correnti M, Avila M, Andea A, DeVilliers P, Rivera H: Keratocystic odontogenic tumor associated with nevoid basal cell carcinoma syndrome: similar behavior to sporadic type? Otolaryngol Head Neck Surg; 2010 Feb;142(2):179-83
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Keratocystic odontogenic tumor associated with nevoid basal cell carcinoma syndrome: similar behavior to sporadic type?
  • OBJECTIVE: The objective of this study was to analyze the expression of proliferative markers and p53 in keratocystic odontogenic tumor (KCOT) sporadic type and KCOT associated with nevoid basal cell carcinoma syndrome (NBCCS).
  • Immunohistochemical analysis for p53, proliferating cell nuclear antigen (PCNA), and Ki-67 was performed in all 19 cases.
  • [MeSH-major] Basal Cell Nevus Syndrome / metabolism. Basal Cell Nevus Syndrome / pathology. Biomarkers, Tumor / analysis. Odontogenic Cysts / metabolism. Odontogenic Cysts / pathology
  • [MeSH-minor] Cross-Sectional Studies. Humans. Immunohistochemistry. Ki-67 Antigen / analysis. Neoplasm Invasiveness. Proliferating Cell Nuclear Antigen / analysis. Tumor Suppressor Protein p53 / analysis

  • Genetic Alliance. consumer health - Nevoid basal cell carcinoma syndrome.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 American Academy of Otolaryngology-Head and Neck Surgery Foundation. Published by Mosby, Inc. All rights reserved.
  • (PMID = 20115971.001).
  • [ISSN] 1097-6817
  • [Journal-full-title] Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery
  • [ISO-abbreviation] Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Proliferating Cell Nuclear Antigen; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


35. Weyers W, Hörster S, Diaz-Cascajo C: Tumor of follicular infundibulum is Basal cell carcinoma. Am J Dermatopathol; 2009 Oct;31(7):634-41
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor of follicular infundibulum is Basal cell carcinoma.
  • Tumor of follicular infundibulum (TFI) is currently thought to be a benign epithelial neoplasm with follicular differentiation.
  • It is encountered commonly in association with basal cell carcinoma (BCC), often as an incidental finding.
  • [MeSH-major] Carcinoma, Basal Cell / classification. Carcinoma, Basal Cell / pathology. Skin Neoplasms / classification. Skin Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19652582.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Brellier F, Bergoglio V, Valin A, Barnay S, Chevallier-Lagente O, Vielh P, Spatz A, Gorry P, Avril MF, Magnaldo T: Heterozygous mutations in the tumor suppressor gene PATCHED provoke basal cell carcinoma-like features in human organotypic skin cultures. Oncogene; 2008 Nov 20;27(51):6601-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Heterozygous mutations in the tumor suppressor gene PATCHED provoke basal cell carcinoma-like features in human organotypic skin cultures.
  • Basal cell carcinoma of the skin is the most common type of cancer in humans.
  • The majority of these tumors displays aberrant activation of the SONIC HEDGEHOG (SHH)/PATCHED pathway, triggered by mutations in the PATCHED tumor suppressor gene, which encodes a transmembrane receptor of SHH.
  • In this study, we took advantage of the natural genotype (PATCHED(+/-)) of healthy keratinocytes expanded from patients with the nevoid basal cell carcinoma or Gorlin syndrome to mimic heterozygous somatic mutations thought to occur in the PATCHED gene early upon basal cell carcinoma development in the general population.
  • Deciphering the phenotype of PATCHED(+/-) keratinocytes revealed slight increases of the transcriptional activators GLI1 and GLI2-the latter known to provoke basal cell carcinoma-like tumors when overexpressed in transgenic mice.
  • PATCHED(+/-) keratinocytes also showed a substantial increase of the cell cycle regulator cyclin D1.
  • [MeSH-major] Carcinoma, Basal Cell / genetics. Mutation. Receptors, Cell Surface / genetics. Skin / pathology. Skin Neoplasms / genetics
  • [MeSH-minor] Base Sequence. Cell Transformation, Neoplastic / genetics. Cells, Cultured. DNA Mutational Analysis. Female. Gene Expression Regulation, Neoplastic. Genes, Tumor Suppressor / physiology. Genetic Predisposition to Disease. Heterozygote. Humans. Keratinocytes / metabolism. Keratinocytes / pathology. Male. Middle Aged. Models, Biological. Organ Culture Techniques


37. Bäckvall H, Asplund A, Gustafsson A, Sivertsson A, Lundeberg J, Ponten F: Genetic tumor archeology: microdissection and genetic heterogeneity in squamous and basal cell carcinoma. Mutat Res; 2005 Apr 1;571(1-2):65-79
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic tumor archeology: microdissection and genetic heterogeneity in squamous and basal cell carcinoma.
  • Detectable lesions occur early during tumor progression, facilitating molecular analysis of the cell populations from both preneoplastic and neoplastic lesions.
  • Alterations of the p53 tumor suppressor gene are very common in non-melanoma skin cancer, and dysregulation of p53 pathways appear to be an early event in the tumor development.
  • The abundance of clones containing p53 mutated keratinocytes adjacent to basal cell (BCC) and squamous cell carcinoma (SCC) suggests a role in human skin carcinogenesis.
  • Here, we present examples of using well-defined cell populations, including single cells, from complex tissue in combination with molecular tools to reveal features involved in skin carcinogenesis.
  • [MeSH-major] Carcinoma, Basal Cell / genetics. Carcinoma, Squamous Cell / genetics. Genetic Heterogeneity. Skin Neoplasms / genetics
  • [MeSH-minor] Humans. Neoplasms, Radiation-Induced / genetics. Ultraviolet Rays

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15748639.001).
  • [ISSN] 0027-5107
  • [Journal-full-title] Mutation research
  • [ISO-abbreviation] Mutat. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 79
  •  go-up   go-down


38. Reis-Filho JS, Milanezi F, Steele D, Savage K, Simpson PT, Nesland JM, Pereira EM, Lakhani SR, Schmitt FC: Metaplastic breast carcinomas are basal-like tumours. Histopathology; 2006 Jul;49(1):10-21
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metaplastic breast carcinomas are basal-like tumours.
  • AIMS: Recently, an immunohistochemical panel comprising antibodies against HER2, oestrogen receptor (ER), epidermal growth factor receptor (EGFR) and cytokeratin (CK) 5/6 was reported to identify basal-like breast carcinomas, as defined by cDNA microarrays.
  • Our aim was to analyse a series of metaplastic breast carcinomas (MBCs) using this panel plus two other basal markers (CK14 and p63) and progesterone receptor (PR), to define how frequently MBCs show a basal-like immunophenotype.
  • All but six cases (91%) showed the typical immunoprofile of basal-like tumours (ER- and HER2-, EGFR+ and/or CK5/6+).
  • When CK14 and p63 were added to the panel, two additional cases could be classified as basal-like.
  • CONCLUSIONS: Our results demonstrate that MBCs show a basal-like phenotype, regardless of the type of metaplastic elements.
  • Moreover, as these neoplasms frequently overexpress EGFR (57%), patients with MBC may benefit from treatment with anti-EGFR drugs.
  • [MeSH-major] Breast Neoplasms / pathology
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Female. Humans. Immunohistochemistry. Keratins / metabolism. Membrane Proteins / metabolism. Metaplasia. Neoplasms, Basal Cell / classification. Neoplasms, Basal Cell / metabolism. Neoplasms, Basal Cell / pathology. Receptor, Epidermal Growth Factor / metabolism. Receptor, ErbB-2 / metabolism. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16842242.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CKAP4 protein, human; 0 / Membrane Proteins; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 68238-35-7 / Keratins; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


39. Levy J, Cagnano E, Benharroch D, Monos T, Lifshitz T: Collision sebaceous and basal cell carcinomas of the eyelid. Ann Diagn Pathol; 2006 Jun;10(3):157-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Collision sebaceous and basal cell carcinomas of the eyelid.
  • OBJECTIVE: To report a rare case of collision sebaceous and basal cell carcinomas of the eyelid.
  • Histopathology showed mixed sebaceous as well as basal cell carcinoma with uninvolved surgical margins.
  • CONCLUSION: Sebaceous and basal cell carcinomas can coexist in the eyelid within the same clinical lesion.
  • [MeSH-major] Adenocarcinoma, Sebaceous / pathology. Carcinoma, Basal Cell / pathology. Eyelid Neoplasms / pathology. Neoplasms, Multiple Primary / pathology
  • [MeSH-minor] Aged, 80 and over. Biomarkers, Tumor / analysis. Female. Humans. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16730311.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


40. Leibovitch I, McNab A, Sullivan T, Davis G, Selva D: Orbital invasion by periocular basal cell carcinoma. Ophthalmology; 2005 Apr;112(4):717-23

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Orbital invasion by periocular basal cell carcinoma.
  • OBJECTIVES: To present a large series of patients with orbital invasion by periocular basal cell carcinoma (BCC).
  • MAIN OUTCOME MEASURES: Patients' demographics, clinical presentation, histologic subtypes, treatment modalities, recurrence rate, and tumor-related death.
  • Only 1 patient (1.6%) died from tumor-related causes.
  • [MeSH-major] Carcinoma, Basal Cell / secondary. Eyelid Neoplasms / pathology. Neoplasm Recurrence, Local. Orbital Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Orbit Evisceration. Peripheral Nervous System Neoplasms / radiotherapy. Peripheral Nervous System Neoplasms / secondary. Peripheral Nervous System Neoplasms / surgery. Radiotherapy. Retrospective Studies. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15808267.001).
  • [ISSN] 1549-4713
  • [Journal-full-title] Ophthalmology
  • [ISO-abbreviation] Ophthalmology
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


41. Chuprov IN: [Immunomorphological features of cutaneous basal-cell carcinoma]. Vopr Onkol; 2008;54(6):715-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Immunomorphological features of cutaneous basal-cell carcinoma].
  • An immunohistochemical study of p53, Ki-67, bcl-2, CK-8 and collagen IV was conducted in 47 basal-cell carcinomas (BCC) to ascertain their prognostic value.
  • CK-8 expression did not vary significantly within the 67.21-71.39% of tumor cells as far as different histotopographic patterns are concerned.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Basal Cell / chemistry. Carcinoma, Basal Cell / pathology. Skin Neoplasms / chemistry. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Basement Membrane / chemistry. Basement Membrane / pathology. Collagen Type IV / analysis. Female. Humans. Immunohistochemistry. Keratin-8 / analysis. Ki-67 Antigen / analysis. Male. Middle Aged. Neoplasm Invasiveness. Proto-Oncogene Proteins c-bcl-2 / analysis. Tumor Suppressor Protein p53 / analysis

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19241845.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Collagen Type IV; 0 / Keratin-8; 0 / Ki-67 Antigen; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


42. Katase N, Nagatsuka H, Tsujigiwa H, Gunduz M, Tamamura R, Pwint HP, Rivera RS, Nakajima M, Naomoto Y, Nagai N: Analysis of the neoplastic nature and biological potential of sporadic and nevoid basal cell carcinoma syndrome-associated keratocystic odontogenic tumor. J Oral Pathol Med; 2007 Oct;36(9):550-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of the neoplastic nature and biological potential of sporadic and nevoid basal cell carcinoma syndrome-associated keratocystic odontogenic tumor.
  • BACKGROUND: Keratocystic odontogenic tumor (KCOT), also known as odontogenic keratocyst, is a benign cystic neoplasm, which may be associated with nevoid basal cell carcinoma syndrome (NBCCS) and if it does, will occur as multiple cystic lesions.
  • [MeSH-major] Basal Cell Nevus Syndrome / enzymology. Glucuronidase / biosynthesis. Odontogenic Cysts / enzymology. Odontogenic Tumors / enzymology
  • [MeSH-minor] Dentigerous Cyst / enzymology. Gene Expression Regulation, Neoplastic. Heparan Sulfate Proteoglycans / metabolism. Humans. Immunohistochemistry. In Situ Hybridization. Neoplasm Invasiveness

  • Genetic Alliance. consumer health - Nevoid basal cell carcinoma syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17850439.001).
  • [ISSN] 0904-2512
  • [Journal-full-title] Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology
  • [ISO-abbreviation] J. Oral Pathol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Heparan Sulfate Proteoglycans; EC 3.2.1.- / heparanase; EC 3.2.1.31 / Glucuronidase
  •  go-up   go-down


43. Erb P, Ji J, Wernli M, Kump E, Glaser A, Büchner SA: Role of apoptosis in basal cell and squamous cell carcinoma formation. Immunol Lett; 2005 Aug 15;100(1):68-72
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of apoptosis in basal cell and squamous cell carcinoma formation.
  • Long-term ultraviolet-light (UV) exposure of human skin epidermis is associated with an increased risk for the development of skin cancers, such as melanoma, basal cell carcinoma (BCC) and squamous cell carcinoma (SCC).
  • If the DNA damage is not repaired or the damaged cells are not eliminated by apoptosis, the consequence can be cell transformation, uncontrolled proliferation and eventually skin tumor formation.
  • Excessive UV exposure can mutate the p53 gene leading to the loss of its repair function and thus apoptosis resistance of the DNA-damaged cell.
  • In addition, BCC and SCC strongly express the apoptosis-inducing Fas-ligand (FasL) which may help the tumor to escape the attack of immune effector cells.
  • Silencing the genes involved in tumor formation by RNA interference might become a promising new approach to treat skin tumors.
  • [MeSH-major] Apoptosis. Carcinoma, Basal Cell / metabolism. Carcinoma, Squamous Cell / metabolism. Gene Expression Regulation, Neoplastic / radiation effects. Signal Transduction / radiation effects. Skin Neoplasms / metabolism. Ultraviolet Rays / adverse effects
  • [MeSH-minor] Animals. DNA Damage / genetics. DNA Damage / radiation effects. Fas Ligand Protein. Hedgehog Proteins. Humans. Membrane Glycoproteins / biosynthesis. Membrane Glycoproteins / genetics. Mice. Mutation. Trans-Activators / genetics. Trans-Activators / metabolism. Tumor Suppressor Protein p53 / genetics. Tumor Suppressor Protein p53 / metabolism

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16054233.001).
  • [ISSN] 0165-2478
  • [Journal-full-title] Immunology letters
  • [ISO-abbreviation] Immunol. Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / FASLG protein, human; 0 / Fas Ligand Protein; 0 / Fasl protein, mouse; 0 / Hedgehog Proteins; 0 / Membrane Glycoproteins; 0 / Trans-Activators; 0 / Tumor Suppressor Protein p53
  • [Number-of-references] 24
  •  go-up   go-down


44. Prabhakaran VC, Gupta A, Huilgol SC, Selva D: Basal cell carcinoma of the eyelids. Compr Ophthalmol Update; 2007 Jan-Feb;8(1):1-14

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma of the eyelids.
  • Basal cell carcinoma is the most common malignancy in humans, and it is also the most frequent periocular malignancy.
  • Although a slow-growing tumor, it can lead to significant morbidity in the periocular region as a result of orbital invasion.
  • Management needs to be individualized, taking into account patient factors, tumor characteristics, and histological subtype.
  • In this review, we discuss the risk factors, pathology, molecular biology, clinical features, and management of eyelid basal cell carcinoma.
  • [MeSH-major] Carcinoma, Basal Cell. Eyelid Neoplasms
  • [MeSH-minor] Australia / epidemiology. Combined Modality Therapy. Diagnosis, Differential. Humans. Incidence. Neoplasm Invasiveness. Orbital Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Compr Ophthalmol Update. 2007 Jan-Feb;8(1):15-6 [17394755.001]
  • (PMID = 17394754.001).
  • [ISSN] 1527-7313
  • [Journal-full-title] Comprehensive ophthalmology update
  • [ISO-abbreviation] Compr Ophthalmol Update
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 119
  •  go-up   go-down


45. Rossman D, Arthurs B, Odashiro A, Saraiva V, Burnier M Jr: Basal cell carcinoma of the caruncle. Ophthal Plast Reconstr Surg; 2006 Jul-Aug;22(4):313-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma of the caruncle.
  • Surgical excision of the lesion was performed, and histopathology showed a nodular basal cell carcinoma of the caruncle.
  • No tumor recurrence was detected in the caruncle after 6 months of follow-up.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Conjunctival Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16855514.001).
  • [ISSN] 0740-9303
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Ly E, Durlach A, Antonicelli F, Bernard P, Manfait M, Piot O: Probing tumor and peritumoral tissues in superficial and nodular basal cell carcinoma using polarized Raman microspectroscopy. Exp Dermatol; 2010 Jan;19(1):68-73
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Probing tumor and peritumoral tissues in superficial and nodular basal cell carcinoma using polarized Raman microspectroscopy.
  • Basal cell carcinoma (BCC) can sometimes lead, through a possible invasion of the dermis and the subcutaneous tissue, to serious local damage to the patient.
  • This study reports the use of polarized Raman microspectroscopy on the nodular and superficial types to discriminate between healthy epidermis and tumor, and between normal and peritumoral stroma.
  • Depolarization ratios and hierarchical cluster analysis demonstrate that polarized Raman microspectroscopy can better identify the tumor and the peritumoral dermis than conventional Raman microspectroscopy, and hence gives potential complementary data about their molecular characteristics (molecular composition, secondary structure of proteins, intra- and/or inter-molecular bonding).
  • [MeSH-major] Carcinoma, Basal Cell / chemistry. Skin Neoplasms / chemistry
  • [MeSH-minor] Cluster Analysis. Dermis / chemistry. Disease Progression. Epidermis / chemistry. Humans. Spectrum Analysis, Raman / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19845756.001).
  • [ISSN] 1600-0625
  • [Journal-full-title] Experimental dermatology
  • [ISO-abbreviation] Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  •  go-up   go-down


47. Nitzki F, Zibat A, König S, Wijgerde M, Rosenberger A, Brembeck FH, Carstens PO, Frommhold A, Uhmann A, Klingler S, Reifenberger J, Pukrop T, Aberger F, Schulz-Schaeffer W, Hahn H: Tumor stroma-derived Wnt5a induces differentiation of basal cell carcinoma of Ptch-mutant mice via CaMKII. Cancer Res; 2010 Apr 1;70(7):2739-48
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor stroma-derived Wnt5a induces differentiation of basal cell carcinoma of Ptch-mutant mice via CaMKII.
  • Basal cell carcinoma (BCC) is the most common skin tumor in humans.
  • The understanding of molecular events mediating spontaneous regression has the potential to reduce morbidity of BCC and, potentially, other tumors, if translated into tumor therapies.
  • Differentiation is accompanied by Wnt5a expression in the tumor stroma, which is first detectable at the fully developed tumor stage.
  • Coculture experiments revealed that Wnt5a is upregulated in tumor-adjacent macrophages by soluble signals derived from BCC cells.
  • In turn, Wnt5a induces the expression of the differentiation marker K10 in tumor cells, which is mediated by Wnt/Ca(2+) signaling in a CaMKII-dependent manner.
  • These data support a role of stromal Wnt5a in BCC differentiation and regression, which may have important implications for development of new treatment strategies for this tumor.
  • Taken together, our results establish BCC as an easily accessible model of tumor regression.
  • The regression of BCC despite sustained Hedgehog signaling activity seems to be mediated by tumor-stromal interactions via Wnt5a signaling.
  • [MeSH-major] Calcium-Calmodulin-Dependent Protein Kinase Type 2 / metabolism. Carcinoma, Basal Cell / metabolism. Skin Neoplasms / metabolism. Wnt Proteins / biosynthesis
  • [MeSH-minor] Animals. Cell Differentiation / physiology. Humans. Macrophages / metabolism. Macrophages / pathology. Mice. Mice, Knockout. NIH 3T3 Cells. Stromal Cells / metabolism. Stromal Cells / pathology. Tamoxifen / pharmacology. Transfection

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20233865.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Wnt Proteins; 0 / Wnt5a protein, mouse; 094ZI81Y45 / Tamoxifen; EC 2.7.11.17 / Calcium-Calmodulin-Dependent Protein Kinase Type 2
  •  go-up   go-down


48. King R, Lyons J, Meyers AL, Googe PB, Page RN, Gupta VK: Primary invasive melanoma and basal cell carcinoma (collision tumor) with blue nevus-like cutaneous metastases. J Cutan Pathol; 2007 Aug;34(8):629-33
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary invasive melanoma and basal cell carcinoma (collision tumor) with blue nevus-like cutaneous metastases.
  • The simultaneous presence of two disparate neoplasms occurring in the same specimen has been well documented, albeit uncommonly.
  • The juxtaposition of malignant melanoma and basal cell carcinoma (BCC) has been rarely reported in case reports, with most cases describing melanoma in situ and BCC.
  • Immunohistochemical studies delineated the two cell populations.
  • The metastases occurred in the same anatomical region as the primary tumor, and histologically consisted of pigmented dendritic melanocytes and melanophages in the superficial and mid-dermis and arranged in a blue nevus-like lesion.
  • Collision tumors containing invasive melanoma and BCC are rare and this is the first report of a collision tumor with blue nevus-like metastasis.
  • [MeSH-major] Carcinoma, Basal Cell / secondary. Melanoma / pathology. Neoplasms, Multiple Primary / pathology. Nevus, Blue / secondary. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Biopsy. Humans. Lymphocytes / pathology. Male. Melanocytes / pathology. Neoplasm Invasiveness

  • Genetic Alliance. consumer health - Nevus.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17640233.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


49. Misago N, Satoh T, Miura Y, Nagase K, Narisawa Y: Merkel cell-poor trichoblastoma with basal cell carcinoma-like foci. Am J Dermatopathol; 2007 Jun;29(3):249-55
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Merkel cell-poor trichoblastoma with basal cell carcinoma-like foci.
  • We reexamined 11 cases of trichoblastoma, and two cases of trichoblastoma with basal cell carcinoma (BCC)-like foci were found.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Hair Diseases / pathology. Hair Follicle / pathology. Merkel Cells / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / analysis. Female. Humans. Immunohistochemistry. Keratin-15 / analysis. Male. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Hair Problems.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17519622.001).
  • [ISSN] 0193-1091
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Keratin-15
  •  go-up   go-down


50. Braun-Falco M: Combined malignant melanoma and basal cell carcinoma tumor of the intermingled type. J Cutan Pathol; 2007 Sep;34(9):731-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined malignant melanoma and basal cell carcinoma tumor of the intermingled type.
  • BACKGROUND: The combination of malignant melanoma (MM) and basal cell carcinoma (BCC) within a single tumor is an unusual finding.
  • CASE REPORT: An 84-year-old white man with a pigmented tumor on the back showing a combination of MM and BCC.
  • Histopathologically, the lesions turned out to be a combined tumor consisting of a superficial BCC and a regressive MM with a tumor thickness of 1.25 mm.
  • CONCLUSION: By reviewing the low number of published cases, we found that a combined MM-BCC tumor exists in two variants: a collision type in which components of each cell type are clearly demarcated and an intermingled type in which both cell types grow intimately together.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Melanoma / pathology. Neoplasms, Multiple Primary / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17696923.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


51. Yu L, Galan A, McNiff JM: Caveats in BerEP4 staining to differentiate basal and squamous cell carcinoma. J Cutan Pathol; 2009 Oct;36(10):1074-176
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Caveats in BerEP4 staining to differentiate basal and squamous cell carcinoma.
  • BACKGROUND: Superficial skin biopsies of basal cell carcinoma (BCC) represent some of the most common dermatopathology specimens.
  • Superficial shave biopsies containing partial samples of lesions with squamatization present difficulties in distinguishing BCC from squamous cell carcinoma (SCC).
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / pathology. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 John Wiley & Sons A/S.
  • (PMID = 19187107.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / human epithelial antigen-125
  •  go-up   go-down


52. Szeimies RM: Methyl aminolevulinate-photodynamic therapy for basal cell carcinoma. Dermatol Clin; 2007 Jan;25(1):89-94
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methyl aminolevulinate-photodynamic therapy for basal cell carcinoma.
  • Basal cell carcinomas (BCCs) are the most common malignant tumors of the skin.
  • Treatment of BCCs should be chosen according to clinical type, tumor size, and location.
  • MAL is licensed in Europe, Australia, New Zealand, and Brazil for the treatment of actinic keratoses, Bowen's disease, and nodular and superficial BCC.
  • [MeSH-major] Aminolevulinic Acid / analogs & derivatives. Carcinoma, Basal Cell / drug therapy. Photochemotherapy. Photosensitizing Agents / therapeutic use. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17126746.001).
  • [ISSN] 0733-8635
  • [Journal-full-title] Dermatologic clinics
  • [ISO-abbreviation] Dermatol Clin
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / methyl 5-aminolevulinate; 88755TAZ87 / Aminolevulinic Acid
  • [Number-of-references] 19
  •  go-up   go-down


53. Nazari Z, Omranipour R: Unusual location of vulvar basal cell carcinoma. J Low Genit Tract Dis; 2006 Oct;10(4):242-4
MedlinePlus Health Information. consumer health - Vulvar Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual location of vulvar basal cell carcinoma.
  • BACKGROUND: Basal cell carcinoma (BCC) is a rare tumor of the vulva; it accounts for approximately 2% to 4% of vulvar cancer.
  • She underwent wide local excision of tumor without any damage to the anal sphincter.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Perineum / pathology. Vulvar Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17012990.001).
  • [ISSN] 1089-2591
  • [Journal-full-title] Journal of lower genital tract disease
  • [ISO-abbreviation] J Low Genit Tract Dis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Chai L, Tang J: [Analysis of 41 cases of basal cell carcinoma in maxillofacial area]. Lin Chuang Er Bi Yan Hou Ke Za Zhi; 2006 Apr;20(7):297-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of 41 cases of basal cell carcinoma in maxillofacial area].
  • OBJECTIVE: To explore the incidence, location and relationship between surgical margin and metastasis of basal cell carcinoma (BCC) in maxillofacial area.
  • In patients who received operation, the difference of the positive rates between 0.3 cm and 0.5 cm of surgical margin of the T1 stage tumor was significant (P<0.05).
  • [MeSH-major] Carcinoma, Basal Cell. Facial Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16780141.001).
  • [Journal-full-title] Lin chuang er bi yan hou ke za zhi = Journal of clinical otorhinolaryngology
  • [ISO-abbreviation] Lin Chuang Er Bi Yan Hou Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


55. Fresini A, Rossiello L, Severino BU, Del Prete M, Satriano RA: Giant basal cell carcinoma. Skinmed; 2007 Jul-Aug;6(4):204-5
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant basal cell carcinoma.
  • A 72-year-old white man presented with a large cutaneous tumor on his back.
  • The tumor mostly showed an adenoid pattern: gland-like structures and cystic spaces sometimes containing amorphous or granular material, surrounded by strands of basaloid cells devoid of any peripheral palisading (Figure 2C).
  • Therefore, a diagnosis of basal cell carcinoma, adenoid subtype, was made.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Skin Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17618177.001).
  • [ISSN] 1540-9740
  • [Journal-full-title] Skinmed
  • [ISO-abbreviation] Skinmed
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Shulman O, Laitman Y, Vilan A, Leviav A, Friedman E: Monoclonal origin of anatomically distinct basal cell carcinomas. J Invest Dermatol; 2006 Mar;126(3):676-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Monoclonal origin of anatomically distinct basal cell carcinomas.
  • Basal cell carcinoma (BCC) is the most common skin tumor in Caucasians.
  • An identical X-chromosome inactivation pattern was noted in all four tumors taken from one patient, and in another informative patient, one tumor demonstrated LOH and the other retained it.
  • We conclude that the majority of anatomically distinct BCCs are monoclonal neoplasms and may represent expansion of the same clone.
  • [MeSH-major] Carcinoma, Basal Cell / genetics. Loss of Heterozygosity. Skin Neoplasms / genetics. X Chromosome Inactivation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Invest Dermatol. 2006 Dec;126(12):2727-9; author reply 2729-30 [16874313.001]
  • (PMID = 16410785.001).
  • [ISSN] 0022-202X
  • [Journal-full-title] The Journal of investigative dermatology
  • [ISO-abbreviation] J. Invest. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. de Meij TG, Baars MJ, Gille JJ, Hack WW, Haasnoot K, van Hagen JM: [From gene to disease: basal cell naevus syndrome]. Ned Tijdschr Geneeskd; 2005 Jan 8;149(2):78-81

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [From gene to disease: basal cell naevus syndrome].
  • Nevoid basal cell carcinoma syndrome (NBCCS, basal cell naevus syndrome, Gorlin syndrome) is an autosomal dominant disorder, caused by mutations in the PTCH gene mapped to chromosome 9q22.3.
  • It is characterised by multiple basal cell carcinomas, keratocysts of the jaws, palmar and plantar pits, cerebral ectopic calcification and several skeletal anomalies.
  • Occasionally, patients with NBCCS develop other neoplasms, particularly medulloblastomas and ovarian fibromas, indicating that the PTCH gene is a tumor-suppressor gene.
  • [MeSH-major] Basal Cell Nevus Syndrome / genetics. Chromosomes, Human, Pair 9. Genes, Tumor Suppressor. Membrane Proteins / genetics. Receptors, Cell Surface / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15688838.001).
  • [ISSN] 0028-2162
  • [Journal-full-title] Nederlands tijdschrift voor geneeskunde
  • [ISO-abbreviation] Ned Tijdschr Geneeskd
  • [Language] dut
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Membrane Proteins; 0 / Receptors, Cell Surface; 0 / patched receptors
  • [Number-of-references] 8
  •  go-up   go-down


58. Patel R, Adsay V, Andea A: Basal cell carcinoma with progression to metastatic neuroendocrine carcinoma. Rare Tumors; 2010;2(1):e8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma with progression to metastatic neuroendocrine carcinoma.
  • Merkel cell carcinoma (MCC) or primary cutaneous neuroendocrine carcinoma is a malignant tumor considered to demonstrate differentiation towards Merkel cells that are present at the base of the epidermis or around the apical end of some hair follicles and are thought to play a yet uncertain role in sensory transduction.
  • Here we present the case of a 54- year old female with a basal cell carcinoma (BCC) of the skin with neuroendocrine features (positivity for chromogranin) that has evolved during multiple recurrences and radiotherapy into a high-grade neuroendocrine carcinoma with morphological and immunohistochemical features of MCC (trabecular and nesting arrangement, positivity for chromogranin, cytokeratin 20, neuron specific enolase, and also neurosecretory granules on electron microscopy).
  • The progression from a chromogranin positive basal cell carcinoma of the skin, to a high-grade neuroendocrine carcinoma demonstrates the potential for cross differentiation among skin tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21139953.001).
  • [ISSN] 2036-3613
  • [Journal-full-title] Rare tumors
  • [ISO-abbreviation] Rare Tumors
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC2994488
  • [Keywords] NOTNLM ; Merkel cell carcinoma / basal cell carcinoma / neuroendocrine
  •  go-up   go-down


59. Heyl J, Mehregan D: Immunolabeling pattern of cytokeratin 19 expression may distinguish sebaceous tumors from basal cell carcinomas. J Cutan Pathol; 2008 Jan;35(1):40-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunolabeling pattern of cytokeratin 19 expression may distinguish sebaceous tumors from basal cell carcinomas.
  • BACKGROUND: Distinction between sebaceous tumors and basal cell carcinomas can often pose diagnostic problems.
  • Our aim was to evaluate the use of CK 19 staining patterns in differentiating between sebaceous tumors and basal cell carcinomas.
  • METHODS: Thirty-seven cases including 5 sebaceous adenomas, 16 sebaceous epitheliomas, 6 sebaceous carcinomas and 14 basal cell carcinomas (7 being of the morpheaform type and 7 nodular basal cell carcinomas) were tested with a monoclonal mouse antibody to human CK 19.
  • CK 19 was found to be strongly positive in 9/14 (64%) and focally positive in 2/14 (14%) of basal cell carcinomas.
  • CONCLUSION: CK 19 expression can be helpful in differentiating sebaceous tumors (including sebaceous adenomas, sebaceous epitheliomas and sebaceous carcinomas) from basal cell carcinomas and may be a useful adjunct when these entities are included in the differential diagnosis.
  • [MeSH-major] Adenocarcinoma, Sebaceous / diagnosis. Adenoma / diagnosis. Biomarkers, Tumor / analysis. Carcinoma, Basal Cell / diagnosis. Keratin-19 / analysis. Sebaceous Gland Neoplasms / diagnosis. Sebaceous Glands / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18095993.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Keratin-19
  •  go-up   go-down


60. Koutlas IG, Koch CA, Vickers RA, Brouwers FM, Vortmeyer AO: An unusual ostensible example of intraoral basal cell carcinoma. J Cutan Pathol; 2009 Apr;36(4):464-70
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An unusual ostensible example of intraoral basal cell carcinoma.
  • An example of oral basal cell carcinoma is presented originating on the posterior mandibular mucosa and gingiva of a 67-year-old female.
  • Tissue samples of the tumor were evaluated with monoclonal antibody Ber-EP4 and were compared with examples of oral mucosa, skin, oral and cutaneous squamous cell carcinoma, peripheral ameloblastoma, ameloblastoma and cutaneous basal cell carcinoma (BCC).
  • Only neoplastic basal cells showed positive immunohistochemical staining.
  • These observations support the inclusion of BCC in the differential diagnosis of appropriate oral mucosal neoplasms.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Mouth Neoplasms / pathology. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Aged. Biomarkers, Tumor / metabolism. Female. Humans. Immunohistochemistry. Loss of Heterozygosity. Receptors, Cell Surface / genetics

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19278434.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Cell Surface; 0 / human epithelial antigen-125; 0 / patched receptors
  •  go-up   go-down


61. Bassi DE, Lopez De Cicco R, Cenna J, Litwin S, Cukierman E, Klein-Szanto AJ: PACE4 expression in mouse basal keratinocytes results in basement membrane disruption and acceleration of tumor progression. Cancer Res; 2005 Aug 15;65(16):7310-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PACE4 expression in mouse basal keratinocytes results in basement membrane disruption and acceleration of tumor progression.
  • Collagen type IV degradation results in disruption and breakdown of the normal basement membrane architecture, a key process in the initiation of tumor microinvasion into the connective tissue.
  • Because PACE4 is overexpressed in skin carcinomas and in vitro overexpression of PACE4 resulted in enhanced invasiveness, we investigated whether or not in vivo PACE4 expression leads to the acquisition of invasiveness and increased tumorigenesis.
  • Two transgenic mouse lines were designed by targeting PACE4 to the epidermal basal keratinocytes.
  • PACE4 overexpression resulted in enhanced susceptibility to carcinogenesis and tumor progression pointing to a new target for blocking tumor cell invasiveness.
  • [MeSH-major] Keratinocytes / enzymology. Serine Endopeptidases / biosynthesis. Skin Neoplasms / enzymology. Skin Neoplasms / pathology
  • [MeSH-minor] Animals. Basement Membrane / enzymology. Basement Membrane / metabolism. Basement Membrane / pathology. Cell Growth Processes / physiology. Disease Progression. Female. Male. Matrix Metalloproteinase 14. Matrix Metalloproteinase 15. Matrix Metalloproteinases, Membrane-Associated. Metalloendopeptidases. Mice. Mice, Transgenic. Proprotein Convertases. Tetradecanoylphorbol Acetate

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. 12-O-TETRADECANOYLPHORBOL-13-ACETATE .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16103082.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA06927; United States / NCI NIH HHS / CA / CA75028
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MMP15 protein, human; 0 / Mmp14 protein, mouse; 0 / Mmp15 protein, mouse; EC 3.4.- / Proprotein Convertases; EC 3.4.21.- / Pcsk6 protein, mouse; EC 3.4.21.- / Serine Endopeptidases; EC 3.4.24.- / Matrix Metalloproteinase 15; EC 3.4.24.- / Matrix Metalloproteinases, Membrane-Associated; EC 3.4.24.- / Metalloendopeptidases; EC 3.4.24.80 / Matrix Metalloproteinase 14; NI40JAQ945 / Tetradecanoylphorbol Acetate
  •  go-up   go-down


62. Alkalay R, Alcalay J, Maly A, Ingber A, Fritsch C, Ruzicka T, Enk CD: Fluorescence imaging for the demarcation of basal cell carcinoma tumor borders. J Drugs Dermatol; 2008 Nov;7(11):1033-7
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fluorescence imaging for the demarcation of basal cell carcinoma tumor borders.
  • BACKGROUND: Basal cell carcinoma (BCC) is a common malignancy accounting for 80% of all nonmelanoma skin cancers.
  • Alternative simpler techniques to facilitate accurate tumor demarcation are therefore in demand.
  • Fluorescence imaging following application of 5-aminolevulinic acid is a noninvasive diagnostic technique that gives rapid information about the superficial extent of the skin tumor.
  • OBJECTIVE: To ascertain whether fluorescence imaging improves the clinical tumor border assessment by investigating the consistency between tumor size determination by MMS, clinical assessment, and fluorescence imaging.
  • The following morning, tumor borders were determined clinically (clinical size), after illumination with Wood's light (fluorescence size), and by the tumor defect left on the skin surface following removal of the MMS specimen (Mohs size).
  • RESULTS: The median tumor sizes were 93.05 mm2 (Mohs size), 61.05 mm2 (clinical size), and 72.75 mm2 (fluorescence size).
  • CONCLUSION: Tumor border estimation by fluorescence imaging and clinical assessment underestimate the genuine tumor size determined by MMS; however, the fluorescence size showed a higher degree of consistency with the Mohs size than did the clinical size.
  • [MeSH-major] Microscopy, Fluorescence. Neoplasms, Basal Cell / pathology. Skin Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19110733.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fluorescent Dyes
  •  go-up   go-down


63. Daya-Grosjean L, Couvé-Privat S: Sonic hedgehog signaling in basal cell carcinomas. Cancer Lett; 2005 Jul 28;225(2):181-92
SciCrunch. KEGG: Data: Disease Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sonic hedgehog signaling in basal cell carcinomas.
  • The development of basal cell carcinoma, the commonest human cancer in fair skinned populations, is clearly associated with constitutive activation of sonic hedgehog signaling.
  • Insight into the genesis of BCC came from the identification of germline mutations of the tumor suppressor gene, PATCHED, a key regulatory component of hedgehog signaling in the nevoid basal cell carcinoma syndrome.
  • Analysis of sporadic basal cell carcinomas and those from repair deficient xeroderma pigmentosum patients has revealed mutational inactivation of PATCHED and gain of function mutations of the proto-oncogenes, SMOOTHENED and SONIC HEDGEHOG associated with solar UV exposure.
  • The molecular mechanisms involved in alterations of the hedgehog signaling pathway that lead to the formation of basal cell carcinomas are being unraveled and has already allowed the investigation of future therapeutic strategies for treating these skin cancers.
  • [MeSH-major] Carcinoma, Basal Cell / metabolism. Signal Transduction. Trans-Activators / metabolism

  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15978322.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Hedgehog Proteins; 0 / SHH protein, human; 0 / Trans-Activators
  • [Number-of-references] 96
  •  go-up   go-down


64. Saglam O, Salama M, Meier F, Chaffins M, Ma C, Ormsby A, Lee M: Immunohistochemical staining of palisading basal cells in Bowen's disease and basal involvement in actinic keratosis: contrasting staining patterns suggest different cells of origin. Am J Dermatopathol; 2008 Apr;30(2):123-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical staining of palisading basal cells in Bowen's disease and basal involvement in actinic keratosis: contrasting staining patterns suggest different cells of origin.
  • Actinic keratosis (AK) and Bowen's disease (BD) are common patterns of in situ squamous cell carcinoma of the epidermis.
  • In AK, atypical keratinocytes proliferate in the lower portion of the epidermis including the basal layer.
  • In contrast, BD features atypical squamous cells in all portions of the epidermis but initially leaves basal cells in palisades along the basement membrane.
  • To characterize immunohistochemically keratocyte proliferation in AK and Palisading Basal Cells (PBC) in BD, we stained microarray samples of 45 AK and 25 BD with Molecular Immunology Borstel (MIB-1).
  • Subsequent immunostaining of full mounted sections examined 11 BD, 7 AK, and 4 examples of psoriasis for MIB-1 (as a proliferative marker) and p53 (as a cell cycle regulatory marker).
  • AK stained for MIB-1 and p53 antibodies only in lower portion of epidermis and included the basal layer.
  • BD with typical PBCs stained positive for both markers throughout the epidermis, except for the basal layer.
  • Psoriatic biopsies stained positively for the 2 markers only in the basal and parabasal layers.
  • Normal epidermis adjacent to the lesions in AK and BD biopsies stained sparsely in the basal layers.
  • Lack of expression of proliferative antigens in palisading basal cells in BD provides evidence that PBCs are not the cell of origin for BD.
  • Conversely in AK, expression of MIB-1 and p53 in basal cells argues that these cells play a role in histogenesis of AK.
  • [MeSH-major] Bowen's Disease / pathology. Carcinoma, Basal Cell / pathology. Keratosis / pathology. Ki-67 Antigen / metabolism. Skin Neoplasms / pathology. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Aged. Aged, 80 and over. Biomarkers, Tumor / genetics. Biopsy, Needle. Cohort Studies. Diagnosis, Differential. Female. Gene Expression Regulation, Neoplastic. Humans. Immunoenzyme Techniques. Immunohistochemistry. Male. Middle Aged. Sensitivity and Specificity. Staining and Labeling / methods

  • Genetic Alliance. consumer health - Bowen's Disease.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18360114.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


65. Schulte KW, Lippold A, Auras C, Bramkamp G, Breitkopf C, Elsmann HJ, Habenicht EM, Jasnoch V, Müller-Pannes H, Rupprecht R, Suter L: Soft x-ray therapy for cutaneous basal cell and squamous cell carcinomas. J Am Acad Dermatol; 2005 Dec;53(6):993-1001
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soft x-ray therapy for cutaneous basal cell and squamous cell carcinomas.
  • BACKGROUND: We have used a schedule for soft x-ray therapy of epithelial malignancies that takes into account the clinically diagnosed tumor involution under treatment.
  • METHODS: Patients with 1267 consecutively irradiated (1988-1992) basal cell and squamous cell carcinomas were followed up (average 77 months).
  • RESULTS: The recurrence rate (5.1%) was related to tumor size and thickness and to the time-dose-fractionation factor.
  • [MeSH-major] Carcinoma, Basal Cell / radiotherapy. Carcinoma, Squamous Cell / radiotherapy. Skin Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Aged, 80 and over. Follow-Up Studies. Humans. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Radiotherapy Dosage. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16310060.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Oldfield V, Keating GM, Perry CM: Imiquimod: in superficial basal cell carcinoma. Am J Clin Dermatol; 2005;6(3):195-200; discussion 201-2
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imiquimod: in superficial basal cell carcinoma.
  • Imiquimod, available as a 5% cream, is a new topical treatment for adults with superficial basal cell carcinoma (BCC).
  • Imiquimod may act as a toll-like receptor-7 agonist, and is thought to exert its anti-tumor effect via modification of the immune response and stimulation of apoptosis in BCC cells.
  • [MeSH-major] Aminoquinolines / pharmacology. Aminoquinolines / therapeutic use. Antineoplastic Agents / pharmacology. Antineoplastic Agents / therapeutic use. Carcinoma, Basal Cell / drug therapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15943496.001).
  • [ISSN] 1175-0561
  • [Journal-full-title] American journal of clinical dermatology
  • [ISO-abbreviation] Am J Clin Dermatol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / Ointments; 99011-02-6 / imiquimod
  • [Number-of-references] 23
  •  go-up   go-down


67. Aragaki T, Michi Y, Katsube K, Uzawa N, Okada N, Akashi T, Amagasa T, Yamaguchi A, Sakamoto K: Comprehensive keratin profiling reveals different histopathogenesis of keratocystic odontogenic tumor and orthokeratinized odontogenic cyst. Hum Pathol; 2010 Dec;41(12):1718-25
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comprehensive keratin profiling reveals different histopathogenesis of keratocystic odontogenic tumor and orthokeratinized odontogenic cyst.
  • Keratocystic odontogenic tumor is a cystic lesion that behaves more aggressively than other jaw cysts.
  • In neonatal rat tooth germ, cells strongly positive for keratin 17 and keratin 19 were observed, specifically in the dental lamina, implying the origin of keratocystic odontogenic tumor.
  • GLI2, a downstream effector of hedgehog signaling, was significantly expressed in keratocystic odontogenic tumor and basal cell carcinoma, accompanied with robust expression of keratin 17, mammalian target of rapamycin, and BCL2.
  • These findings provide evidence to support the viewpoint that keratocystic odontogenic tumor and orthokeratinized odontogenic cyst are separate entities, and furthermore suggest their characteristic histology, pathogenesis, and biological behaviors.
  • [MeSH-major] Jaw Neoplasms / metabolism. Keratins / metabolism. Membrane Proteins / metabolism. Odontogenic Cysts / metabolism. Odontogenic Tumors / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Animals. Animals, Newborn. Carcinoma, Basal Cell / metabolism. Carcinoma, Basal Cell / pathology. Carcinoma, Basal Cell / surgery. Child. Epithelial Cells / metabolism. Epithelial Cells / pathology. Female. Fluorescent Antibody Technique, Indirect. Humans. Kruppel-Like Transcription Factors / metabolism. Male. Middle Aged. Nuclear Proteins / metabolism. Proto-Oncogene Proteins c-bcl-2 / metabolism. Rats. TOR Serine-Threonine Kinases / metabolism. Young Adult

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20801488.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / GLI2 protein, human; 0 / Kruppel-Like Transcription Factors; 0 / Membrane Proteins; 0 / Nuclear Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / loricrin; 68238-35-7 / Keratins; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases
  •  go-up   go-down


68. Zhou M, Magi-Galluzzi C, Epstein JI: Prostate basal cell lesions can be negative for basal cell keratins: a diagnostic pitfall. Anal Quant Cytol Histol; 2006 Jun;28(3):125-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostate basal cell lesions can be negative for basal cell keratins: a diagnostic pitfall.
  • BACKGROUND: Prostate basal cell lesions can have architectural and cytologic atypia that mimic prostate adenocarcinoma.
  • Immunohistochemical stains for basal cell markers are most helpful in the differential diagnosis.
  • All of the published studies show basal cell lesions are positive for basal cell keratins, whereas adenocarcinoma is negative for both.
  • We reported two cases of prostate basal cell lesions with negative basal cell keratin expression by immunohistochemistry.
  • STUDY DESIGN: We reported the histologic and immunohistochemical profiles of two cases of basal cell lesions of the prostate.
  • The atypical glands in both cases were negative for basal cell keratins.
  • However, both lesions were positive for another basal cell marker, p63, confirming that they were basal cells in origin, rather than prostate adenocarcinoma.
  • CONCLUSION: Prostate basal cell lesions can occasionally be negative for basal cell keratins by immunohistochemistry and therefore may be misdiagnosed as prostate adenocarcinoma.
  • We recommend using both p63 and basal cell keratins simultaneously in the workup of atypical prostate lesions to avoid such a misdiagnosis.

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16786721.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CKAP4 protein, human; 0 / Membrane Proteins; 68238-35-7 / Keratins
  •  go-up   go-down


69. Elamin I, Zecević RD, Vojvodić D, Medenica L, Pavlović MD: Cytokine concentrations in basal cell carcinomas of different histological types and localization. Acta Dermatovenerol Alp Pannonica Adriat; 2008 Jun;17(2):55-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytokine concentrations in basal cell carcinomas of different histological types and localization.
  • BACKGROUND: Basal cell carcinoma (BCC) is the most common malignant skin tumor.
  • Cytokines as major mediators of the immune system have been shown to play an important role in biology of the neoplasm with the general predomination of Th2 cytokines, whereas IFN-?
  • OBJECTIVE: We were interested in comparing cytokine levels in BCC and cutaneous squamous cell tumors with BCC of different localization and histological subtypes.
  • MATERIAL AND METHODS: Explants from freshly excised BCC from 18 patients, and cutaneous squamous cell tumors (solar keratoses and Bowen's disease) from 9 patients were cultivated for 24 h.
  • RESULTS: Tissue explants of BCC contained significantly higher concentrations of IL-1beta, IL-4, IL-5, and IL-6 compared to those of squamous cell tumors.
  • CONCLUSIONS: Confirming the earlier findings that BCC is a tumor with a Th2 cytokine microenvironment, this study further shows that BCC situated on the head and neck produce even more of certain Th2 cytokines (IL-4 and IL-5) and TNF-alpha, a crucial immunosuppressive cytokine released upon UVB irradiation.
  • [MeSH-major] Carcinoma, Basal Cell / chemistry. Cytokines / analysis. Skin Neoplasms / chemistry
  • [MeSH-minor] Aged. Carcinoma, Squamous Cell / chemistry. Female. Humans. Interleukin-4 / analysis. Interleukin-5 / analysis. Male. Tumor Necrosis Factor-alpha / analysis

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18709290.001).
  • [ISSN] 1318-4458
  • [Journal-full-title] Acta dermatovenerologica Alpina, Pannonica, et Adriatica
  • [ISO-abbreviation] Acta Dermatovenerol Alp Pannonica Adriat
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Slovenia
  • [Chemical-registry-number] 0 / Cytokines; 0 / Interleukin-5; 0 / Tumor Necrosis Factor-alpha; 207137-56-2 / Interleukin-4
  •  go-up   go-down


70. Wienke D, Davies GC, Johnson DA, Sturge J, Lambros MB, Savage K, Elsheikh SE, Green AR, Ellis IO, Robertson D, Reis-Filho JS, Isacke CM: The collagen receptor Endo180 (CD280) Is expressed on basal-like breast tumor cells and promotes tumor growth in vivo. Cancer Res; 2007 Nov 1;67(21):10230-40
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The collagen receptor Endo180 (CD280) Is expressed on basal-like breast tumor cells and promotes tumor growth in vivo.
  • Tumor cell invasion into the surrounding stroma requires increased cell motility and extensive remodeling of the extracellular matrix.
  • Endo180 (CD280, MRC2, urokinase-type plasminogen activator receptor-associated protein) is a recycling endocytic receptor that functions in both these cellular activities by promoting cell migration and uptake of collagens for intracellular degradation.
  • The contrary observation that Endo180 is expressed on epithelial tumor cell lines that display a high invasive capacity suggested that up-regulation of this receptor may be an associated and functional component in the acquisition of a more aggressive phenotype by tumor cells in vivo.
  • Here, we show that high levels of Endo180 are found in a subset of basal-like breast cancers and that this expression is an independent prognostic marker for shorter disease-free survival.
  • Expression of wild-type Endo180, but not an internalization-defective Endo180 mutant, resulted in enhanced tumor growth together with a reduction in tumor collagen content.
  • Together, these data argue that elevated expression of this receptor in tumor cells could have important consequences in subsets of basal-like carcinomas for which there is a current lack of effective treatment.
  • [MeSH-major] Breast Neoplasms / pathology. Receptors, Mitogen / physiology
  • [MeSH-minor] Animals. Cell Line, Tumor. Female. Gene Expression Regulation, Neoplastic. Humans. Mice. Mice, Inbred BALB C. Neoplasm Invasiveness. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17974964.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Endo180; 0 / Receptors, Mitogen
  •  go-up   go-down


71. Chen BY, Liu JY, Chang HH, Chang CP, Lo WY, Kuo WH, Yang CR, Lin DP: Hedgehog is involved in prostate basal cell hyperplasia formation and its progressing towards tumorigenesis. Biochem Biophys Res Commun; 2007 Jun 15;357(4):1084-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hedgehog is involved in prostate basal cell hyperplasia formation and its progressing towards tumorigenesis.
  • The role of Hedgehog signaling in human basal cell hyperplasia formation and its progressing towards tumorigenesis was investigated.
  • Hedgehog signaling members including PTCH1, GLI1, GLI2, and GLI3 were found co-localized with p63 expression in most hyperplastic basal cells, but rarely in normal basal cells, suggesting Hedgehog involvement in basal cell hyperplasia formation.
  • Both CK-14 and CK-8 markers were found co-localized in the majority of hyperplastic basal cells, but relatively few in the normal basal cells, indicating a Hedgehog-promoted transitory differentiation.
  • Furthermore, CK-14 and PTCH1 were found co-localized with CD44 in the hyerplastic basal cells, in a way similar to the CD44 co-localization with PTCH1 and GLI1 in the cancer cells.
  • Together, the present study indicated Hedgehog involvement in forming basal cell hyperplasia and its progressing towards cancer, presumably by transforming the normal basal stem cells into the cancer stem cells where persistent Hedgehog activation might be mandatory for tumorigenesis.
  • [MeSH-major] Cell Transformation, Neoplastic / metabolism. Hedgehog Proteins / metabolism. Prostatic Hyperplasia / metabolism. Prostatic Hyperplasia / pathology. Prostatic Neoplasms / metabolism. Prostatic Neoplasms / pathology. Stem Cells / metabolism. Stem Cells / pathology
  • [MeSH-minor] Humans. Male. Prostate / metabolism. Prostate / pathology. Tumor Cells, Cultured


72. Pham TT, Selim MA, Burchette JL Jr, Madden J, Turner J, Herman C: CD10 expression in trichoepithelioma and basal cell carcinoma. J Cutan Pathol; 2006 Feb;33(2):123-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD10 expression in trichoepithelioma and basal cell carcinoma.
  • BACKGROUND: Trichoepithelioma (TE) is a benign neoplasm that shares both clinical and histologic features with basal cell carcinoma (BCC).
  • However, it is important to distinguish these neoplasms.
  • Cases were analyzed for pattern of CD10 expression by tumor cells and surrounding stroma.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Basal Cell / metabolism. Neoplasms, Basal Cell / metabolism. Neprilysin / metabolism. Skin Neoplasms / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16420307.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


73. Raouf A: Basal-like breast cancers: the phenotypic disparity between the cancer-initiating cells and tumor histology. Breast Cancer Res; 2010;12(6):316
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal-like breast cancers: the phenotypic disparity between the cancer-initiating cells and tumor histology.
  • Recent evidence suggests that a rare-cell population with a stem cell phenotype maintains breast tumors.
  • Currently, very little is known about the origin of cancer stem cells and their relationship to the tumor phenotype.
  • A recent study from Smalley's group demonstrates that targeting an inactivating Brca1 mutation to the luminal progenitors could yield basal-like breast cancers.
  • [MeSH-major] Breast Neoplasms / pathology. Genes, BRCA1. Neoplasms, Basal Cell / pathology. Neoplastic Stem Cells / pathology

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2002 Dec 19;347(25):1999-2009 [12490681.001]
  • [Cites] Trends Endocrinol Metab. 2004 Jul;15(5):193-7 [15223047.001]
  • [Cites] Zentralbl Allg Pathol. 1985;130(4):323-31 [3911652.001]
  • [Cites] Nat Med. 1997 Jul;3(7):730-7 [9212098.001]
  • [Cites] Nature. 2006 Jan 5;439(7072):84-8 [16397499.001]
  • [Cites] Nature. 2006 Feb 23;439(7079):993-7 [16395311.001]
  • [Cites] BMC Genomics. 2006;7:96 [16643655.001]
  • [Cites] Cell Stem Cell. 2008 Jul 3;3(1):109-18 [18593563.001]
  • [Cites] Cell Stem Cell. 2007 Nov;1(5):555-67 [18371393.001]
  • [Cites] J Clin Oncol. 2009 Mar 10;27(8):1160-7 [19204204.001]
  • [Cites] Nat Med. 2009 Aug;15(8):907-13 [19648928.001]
  • [Cites] Breast Cancer Res Treat. 2010 Jun;121(3):575-89 [19688261.001]
  • [Cites] Cell Stem Cell. 2010 Sep 3;7(3):403-17 [20804975.001]
  • (PMID = 21172068.001).
  • [ISSN] 1465-542X
  • [Journal-full-title] Breast cancer research : BCR
  • [ISO-abbreviation] Breast Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Receptors, Estrogen
  • [Other-IDs] NLM/ PMC3046428
  •  go-up   go-down


74. Man YG, Shen T, Zhao Y, Amy Sang QX: Focal prostate basal cell layer disruptions and leukocyte infiltration are correlated events: A potential mechanism for basal cell layer disruptions and tumor invasion. Cancer Detect Prev; 2005;29(2):161-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Focal prostate basal cell layer disruptions and leukocyte infiltration are correlated events: A potential mechanism for basal cell layer disruptions and tumor invasion.
  • To assess the potential correlation between basal cell layer disruptions and leukocyte infiltration, consecutive sections of normal (n=5) and tumor (n=50) prostate tissues were double immunostained for cytokeratin 34betaE12 (CK 34betaE12) plus leukocyte common antigen, Ki-67, or proliferating cell nuclear antigen (PCNA).
  • Of 2047 acini and ducts examined, 201 contained focal basal cell layer disruptions.
  • Of those, 183 (91%) showed leukocyte infiltration, compared to 67 (33.3%) in 201 morphologically comparable structures with an intact basal cell layer (P<0.01).
  • Basal cell layers adjacent to or surrounded by leukocytes were often attenuated or fragmented, and leukocytes were generally located at or near disruptions.
  • Disrupted basal cell layers showed a markedly reduced proliferation rate, compared to their non-disrupted counterparts.
  • Cells overlying focal basal cell layer disruptions often displayed distinct changes in the size, nuclear shape, density, and polarity, compared to those away from disruptions.
  • A vast majority of proliferating tumor cells were located at or near basal cell layer disruptions.
  • These findings suggest that focal basal cell layer disruptions and leukocyte infiltration are correlated events, representing a potential trigger factor for prostate tumor invasion.
  • [MeSH-major] Epithelial Cells / physiology. Leukocytes / physiology. Neoplasm Invasiveness / physiopathology. Neoplasm Invasiveness / prevention & control. Prostatic Neoplasms / pathology
  • [MeSH-minor] Cell Aggregation. Cell Death. Humans. Immunoassay. Ki-67 Antigen / analysis. Male. Proliferating Cell Nuclear Antigen / analysis

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15829376.001).
  • [ISSN] 0361-090X
  • [Journal-full-title] Cancer detection and prevention
  • [ISO-abbreviation] Cancer Detect. Prev.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA78646
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Proliferating Cell Nuclear Antigen
  •  go-up   go-down


75. Son KD, Kim TJ, Lee YS, Park GS, Han KT, Lim JS, Kang CS: Comparative analysis of immunohistochemical markers with invasiveness and histologic differentiation in squamous cell carcinoma and basal cell carcinoma of the skin. J Surg Oncol; 2008 Jun 1;97(7):615-20
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative analysis of immunohistochemical markers with invasiveness and histologic differentiation in squamous cell carcinoma and basal cell carcinoma of the skin.
  • BACKGROUND: This study evaluates several tumor-related markers to examine the expression pattern of markers according to the invasiveness and histopathologic differentiation of squamous cell carcinoma and basal cell carcinoma.
  • METHODS: Ninety-four cases of squamous cell carcinoma and 108 cases of basal cell carcinoma using tissue array in order to determine correlations between the expression of Ki-67, p53, EGFR, CD44v6, MMP-1 and MMP-3, invasiveness and histologic differentiation.
  • RESULTS: The depth of invasion showed a correlation with CD44v6 expression of tumor cell in both squamous cell carcinoma and basal cell carcinoma (P = 0.009, P = 0.036, respectively) and with the MMP-1 expression of stromal cell in squamous cell carcinoma (P = 0.010).
  • The differentiation of squamous cell carcinoma was correlated with Ki-67 index.
  • The loss of palisading arrangement in basal cell carcinoma was correlated with the MMP-1 expression of stromal cells (P = 0.045).
  • CONCLUSIONS: CD44v6 and MMP-1, expressed in tumor cells and stromal cells respectively, are significant markers associated with the invasiveness of tumors in squamous cell carcinoma and basal cell carcinoma of the skin and that it will be helpful to evaluate the invasiveness by measuring the expression of these markers.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD44 / biosynthesis. Female. Genes, erbB-1. Humans. Immunohistochemistry. Ki-67 Antigen / biosynthesis. Male. Matrix Metalloproteinase 1 / biosynthesis. Matrix Metalloproteinase 3 / biosynthesis. Middle Aged. Neoplasm Invasiveness. Tumor Suppressor Protein p53 / biosynthesis

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18404670.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Biomarkers, Tumor; 0 / CD44 protein, human; 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53; EC 3.4.24.17 / Matrix Metalloproteinase 3; EC 3.4.24.7 / Matrix Metalloproteinase 1
  •  go-up   go-down


76. Newman JC, Leffell DJ: Correlation of embryonic fusion planes with the anatomical distribution of basal cell carcinoma. Dermatol Surg; 2007 Aug;33(8):957-64; discussion 965
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of embryonic fusion planes with the anatomical distribution of basal cell carcinoma.
  • BACKGROUND: The clinical relevance of the anatomic distribution of basal cell carcinoma is not completely understood.
  • Embryonic fusion planes--the regions of mesenchymal migration and fusion of the five primordial facial processes during the 5th to 10th weeks of human development--have been implicated in the pathogenesis of basal cell carcinoma.
  • OBJECTIVE: This study sought to examine the predilection of midfacial basal cell carcinoma for cutaneous anatomical sites correlated to embryonic fusion planes.
  • METHODS AND MATERIALS: Using archived digital images and a detailed anatomic diagram, cases of basal cell carcinoma were coded according to their specific location and were aggregated into two anatomic domains according to their correlation to embryonic fusion planes.
  • The relative tumor densities were calculated.
  • The relative tumor density of lesions in the fusion plane domain was 3.06 compared to 0.74 for the remaining lesions (p< .001).
  • CONCLUSIONS: Although there is no consensus about the importance of anatomic location in the pathogenesis of basal cell carcinoma, these data indicate that, after adjusting for surface area, basal cell carcinoma was more than four times more likely to occur on an embryonic fusion plane than on other regions of the midface.
  • These data support the possibility of an embryologic role for the pathogenesis of basal cell carcinoma.
  • [MeSH-major] Carcinoma, Basal Cell / embryology. Carcinoma, Basal Cell / pathology. Facial Neoplasms / embryology. Facial Neoplasms / pathology. Skin Neoplasms / embryology. Skin Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Dermatol Surg. 2008 Jun;34(6):851-3; author reply 853 [18384370.001]
  • (PMID = 17661939.001).
  • [ISSN] 1076-0512
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


77. Yehiely F, Moyano JV, Evans JR, Nielsen TO, Cryns VL: Deconstructing the molecular portrait of basal-like breast cancer. Trends Mol Med; 2006 Nov;12(11):537-44
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Deconstructing the molecular portrait of basal-like breast cancer.
  • Basal-like tumors are a newly recognized subtype of breast cancer, which express genes that are characteristic of basal epithelial cells, such as the basal cytokeratins, and are associated with poor relapse-free and overall survival.
  • Here, we focus on new insights into the molecular pathogenesis of basal-like breast cancer and explore how these discoveries might impact the treatment of these poor-prognosis tumors.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17011236.001).
  • [ISSN] 1471-4914
  • [Journal-full-title] Trends in molecular medicine
  • [ISO-abbreviation] Trends Mol Med
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / T32 GM008152; United States / NCI NIH HHS / CA / P50 CA 89018; United States / NCI NIH HHS / CA / R01 CA 097198
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / BRCA1 Protein; 0 / Biomarkers, Tumor; 0 / beta-Crystallin A Chain; EC 2.7.10.1 / Receptor, ErbB-2
  • [Number-of-references] 80
  •  go-up   go-down


78. Corrêa Mde P, Ferreira AP, Gollner AM, Rodrigues MF, Guerra MC: [Markers expression of cell proliferation and apoptosis in basal cell carcinoma]. An Bras Dermatol; 2009 Nov-Dec;84(6):606-14
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Markers expression of cell proliferation and apoptosis in basal cell carcinoma].
  • [Transliterated title] Expressão de marcadores de proliferação celular e apoptose em carcinoma basocelular.
  • BACKGROUND: - Basal cell carcinoma is the most common form of human cancer.
  • OBJECTIVE - To correlate markers expression of apoptosis (p53 and bcl-2) and cell proliferation (Ki-67 and PCNA) with histological indicators of tumor severity.
  • The Mann-Whitney test was used to compare these markers expression with the manifestation form of basal cell carcinoma.
  • RESULTS - Bcl-2 expression was significant in basal cell carcinomas said to be aggressive (morpheaform and nodular types).
  • Of the studied tumors, 66.7% (n =10) strongly expressed p53.Our results show a greater expression of Ki-67 in nodular and superficial basal cell carcinoma, with no expression in the controls.
  • CONCLUSION - The findings allow us to conclude that Bcl-2 and p53 show a tendency to indicate the severity of basal cell carcinoma.
  • Also, PCNA was not a good marker of cell proliferation.
  • [MeSH-major] Apoptosis. Biomarkers, Tumor / analysis. Carcinoma, Basal Cell / chemistry. Carcinoma, Basal Cell / pathology. Cell Proliferation. Skin Neoplasms / chemistry. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20191172.001).
  • [ISSN] 1806-4841
  • [Journal-full-title] Anais brasileiros de dermatologia
  • [ISO-abbreviation] An Bras Dermatol
  • [Language] por
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


79. Kim DY, Cho SB, Chung KY, Kim YC: Clear cell basal cell carcinoma with sialomucin deposition. Yonsei Med J; 2006 Dec 31;47(6):870-2

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell basal cell carcinoma with sialomucin deposition.
  • Clear cell basal cell carcinoma (BCC) is a variant of BCC with a characteristic clear cell component that may occupy all or part of the tumor islands.
  • However, to our knowledge, clear cell BCC with sialomucin deposition has not been reported.
  • Here we report a case of clear cell BCC showing sialomucin deposition.
  • The clear tumor cells stained with PAS and showed incomplete diastase-resistance.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Sialomucins / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Pathol. 2000 Oct;53(10):742-9 [11064666.001]
  • [Cites] Am J Dermatopathol. 2004 Aug;26(4):298-303 [15249860.001]
  • [Cites] J Cutan Pathol. 1988 Feb;15(1):1-7 [3351059.001]
  • [Cites] J Cutan Pathol. 1988 Dec;15(6):404-8 [3221000.001]
  • [Cites] Histopathology. 1990 Nov;17(5):401-5 [1706297.001]
  • [Cites] J Cutan Pathol. 1993 Aug;20(4):308-16 [8227606.001]
  • [Cites] Histopathology. 1998 May;32(5):393-8 [9639112.001]
  • [Cites] Ann Plast Surg. 1999 Aug;43(2):215-7 [10454334.001]
  • [Cites] AMA Arch Derm Syphilol. 1953 Jun;67(6):598-615 [13050184.001]
  • (PMID = 17191318.001).
  • [ISSN] 0513-5796
  • [Journal-full-title] Yonsei medical journal
  • [ISO-abbreviation] Yonsei Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Sialomucins
  • [Other-IDs] NLM/ PMC2687829
  •  go-up   go-down


80. Wang X, Ramirez A, Budunova I: Overexpression of connexin26 in the basal keratinocytes reduces sensitivity to tumor promoter TPA. Exp Dermatol; 2010 Jul 1;19(7):633-40
Hazardous Substances Data Bank. 12-O-TETRADECANOYLPHORBOL-13-ACETATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of connexin26 in the basal keratinocytes reduces sensitivity to tumor promoter TPA.
  • Cx26 is barely expressed in normal adult epidermis, but its expression is induced during wound healing, psoriasis, and skin hyperplasia stimulated by tumor promoters.
  • In hyperplastic proliferating epidermis, Cx26 is co-expressed with Cx43 typical for basal and suprabasal keratinocytes.
  • To test the effect of persistent co-expression of Cx26 and Cx43 in epidermis, we generated transgenic mice using keratin5 promoter to target Cx26 to basal Cx43-positive keratinocytes.
  • Unexpectedly, the proliferative effect of tumor promoter TPA was strongly decreased in epidermis of K5.Cx26 transgenics.
  • [MeSH-minor] Animals. Cattle. Cell Differentiation / drug effects. Cell Proliferation / drug effects. Gene Expression. Keratin-5 / genetics. Mice. Mice, Transgenic. Promoter Regions, Genetic. Protein Kinase C / metabolism. Rats. Recombinant Proteins / genetics. Recombinant Proteins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20002174.001).
  • [ISSN] 1600-0625
  • [Journal-full-title] Experimental dermatology
  • [ISO-abbreviation] Exp. Dermatol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA 82718
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Carcinogens; 0 / Connexins; 0 / Keratin-5; 0 / Recombinant Proteins; 127120-53-0 / connexin 26; EC 2.7.11.13 / Protein Kinase C; NI40JAQ945 / Tetradecanoylphorbol Acetate
  •  go-up   go-down


81. Krahl D, Sellheyer K: Monoclonal antibody Ber-EP4 reliably discriminates between microcystic adnexal carcinoma and basal cell carcinoma. J Cutan Pathol; 2007 Oct;34(10):782-7
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Monoclonal antibody Ber-EP4 reliably discriminates between microcystic adnexal carcinoma and basal cell carcinoma.
  • BACKGROUND: Sclerosing cutaneous neoplasms often represent a diagnostic challenge.
  • It is diagnostically highly reliable in the differentiation between basal cell carcinoma and cutaneous squamous cell carcinoma.
  • In this study, we report its application in the differential diagnosis of microcystic adnexal carcinoma, desmoplastic trichoepithelioma and basal cell carcinoma.
  • METHODS: Biopsy samples from 28 sclerosing and infiltrating basal cell carcinomas, 13 microcystic adnexal carcinomas and 16 desmoplastic trichoepitheliomas were examined after immunohistochemical staining with Ber-EP4.
  • RESULTS: Ber-EP4 did not label any of the microcystic adnexal carcinomas, whereas all 28 basal cell carcinomas were Ber-EP4 positive.
  • Only one basal cell carcinoma was weakly positive.
  • Twelve of the 16 desmoplastic trichoepitheliomas were immunoreactive with Ber-EP4 and the staining was more variable than those of basal cell carcinomas.
  • CONCLUSIONS: Ber-EP4 reliably differentiates microcystic adnexal carcinoma from basal cell carcinoma to the same extent as it distinguishes the latter tumor from squamous cell carcinoma.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Basal Cell / diagnosis. Carcinoma, Skin Appendage / diagnosis. Skin / pathology. Skin Neoplasms / diagnosis
  • [MeSH-minor] Biopsy. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / metabolism. Diagnosis, Differential. Fluorescent Antibody Technique, Indirect. Humans. Sclerosis / pathology

  • Genetic Alliance. consumer health - Microcystic adnexal carcinoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17880584.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / human epithelial antigen-125
  •  go-up   go-down


82. Sambade MJ, Kimple RJ, Camp JT, Peters E, Livasy CA, Sartor CI, Shields JM: Lapatinib in combination with radiation diminishes tumor regrowth in HER2+ and basal-like/EGFR+ breast tumor xenografts. Int J Radiat Oncol Biol Phys; 2010 Jun 1;77(2):575-81
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lapatinib in combination with radiation diminishes tumor regrowth in HER2+ and basal-like/EGFR+ breast tumor xenografts.
  • PURPOSE: To determine whether lapatinib, a dual epidermal growth factor receptor (EGFR)/HER2 kinase inhibitor, can radiosensitize EGFR+ or HER2+ breast cancer xenografts.
  • METHODS AND MATERIALS: Mice bearing xenografts of basal-like/EGFR+ SUM149 and HER2+ SUM225 breast cancer cells were treated with lapatinib and fractionated radiotherapy and tumor growth inhibition correlated with alterations in ERK1 and AKT activation by immunohistochemistry.
  • RESULTS: Basal-like/EGFR+ SUM149 breast cancer tumors were completely resistant to treatment with lapatinib alone but highly growth impaired with lapatinib plus radiotherapy, exhibiting an enhancement ratio average of 2.75 and a fractional tumor product ratio average of 2.20 during the study period.
  • Durable tumor control in the HER2+ SUM225 model was more effective with the combination treatment than either lapatinib or radiotherapy alone.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • [Cites] Cancer Res. 2000 Apr 15;60(8):2190-6 [10786683.001]
  • [Cites] BMC Genomics. 2007;8:258 [17663798.001]
  • [Cites] Oncogene. 2002 Sep 12;21(41):6255-63 [12214266.001]
  • [Cites] Mol Cancer Ther. 2001 Dec;1(2):85-94 [12467226.001]
  • [Cites] Semin Radiat Oncol. 2003 Jan;13(1):22-30 [12520461.001]
  • [Cites] Oncogene. 2003 Sep 1;22(37):5855-65 [12947392.001]
  • [Cites] Breast Cancer. 2003;10(3):268-74 [12955041.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2004;44:195-217 [14744244.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Feb 1;58(2):344-52 [14751502.001]
  • [Cites] Breast J. 2004 May-Jun;10(3):204-10 [15125746.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Jul 15;59(4):1163-73 [15234052.001]
  • [Cites] Clin Cancer Res. 2004 Oct 1;10(19):6487-501 [15475436.001]
  • [Cites] J Clin Oncol. 2005 Feb 20;23(6):1152-60 [15718311.001]
  • [Cites] Radiother Oncol. 2005 Feb;74(2):109-15 [15734198.001]
  • [Cites] J Clin Oncol. 2005 Apr 10;23(11):2502-12 [15684311.001]
  • [Cites] Nat Clin Pract Oncol. 2004 Dec;1(2):80-7 [16264825.001]
  • [Cites] N Engl J Med. 2006 Feb 9;354(6):567-78 [16467544.001]
  • [Cites] Breast Cancer Res Treat. 2006 Feb;95(3):243-55 [16261404.001]
  • [Cites] Clin Cancer Res. 2007 Apr 15;13(8):2329-34 [17438091.001]
  • [Cites] Breast Cancer Res. 2007;9(5):R61 [17875215.001]
  • [Cites] Nat Clin Pract Oncol. 2008 Mar;5(3):149-59 [18212769.001]
  • [Cites] J Clin Oncol. 2008 Mar 1;26(7):1066-72 [18212337.001]
  • [Cites] J Clin Oncol. 2008 May 20;26(15):2568-81 [18487574.001]
  • [Cites] Cancer Metastasis Rev. 2008 Sep;27(3):387-402 [18427731.001]
  • [Cites] J Natl Cancer Inst. 2008 Aug 6;100(15):1092-103 [18664652.001]
  • [Cites] Breast Cancer Res Treat. 2008 Dec;112(3):533-43 [18188694.001]
  • [Cites] Clin Cancer Res. 2008 Dec 1;14(23):7900-8 [19047120.001]
  • [Cites] Cancer Res. 2009 Jan 15;69(2):565-72 [19147570.001]
  • [Cites] Curr Opin Cell Biol. 2009 Apr;21(2):177-84 [19208461.001]
  • [Cites] Lancet Oncol. 2009 May;10(5):522-7 [19410197.001]
  • [Cites] Ann Oncol. 2009 Jun;20(6):1026-31 [19179558.001]
  • [Cites] Lancet Oncol. 2009 Jun;10(6):581-8 [19394894.001]
  • [Cites] Breast Cancer Res Treat. 2009 Jul;116(2):317-28 [18839307.001]
  • [Cites] Cancer Chemother Pharmacol. 2009 Nov;64(6):1139-48 [19294387.001]
  • [Cites] Radiother Oncol. 2009 Dec;93(3):639-44 [19853943.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2010 Mar 15;76(4):998-1004 [19560883.001]
  • [Cites] Nat Clin Pract Oncol. 2006 Sep;3(9):463 [16955079.001]
  • [Cites] N Engl J Med. 2006 Dec 28;355(26):2733-43 [17192538.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Dec 1;48(5):1519-28 [11121658.001]
  • (PMID = 20457354.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA130159-01; United States / NCI NIH HHS / CA / CA115888-04; United States / NCI NIH HHS / CA / L30 CA130159; United States / NCI NIH HHS / CA / K08 CA083753; United States / NCI NIH HHS / CA / CA115888-03; United States / NCI NIH HHS / CA / R01 CA115888; United States / NCI NIH HHS / CA / CA83753; United States / NCI NIH HHS / CA / CA115888; United States / NCI NIH HHS / CA / L30 CA130159-01; United States / NCI NIH HHS / CA / R01 CA115888-03; United States / NCI NIH HHS / CA / R01 CA115888-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / Protein Kinase Inhibitors; 0 / Quinazolines; 0 / Radiation-Sensitizing Agents; 0VUA21238F / lapatinib; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3
  • [Other-IDs] NLM/ NIHMS243711; NLM/ PMC2976524
  •  go-up   go-down


83. Basyuk E, Coulon V, Le Digarcher A, Coisy-Quivy M, Moles JP, Gandarillas A, Journot L: The candidate tumor suppressor gene ZAC is involved in keratinocyte differentiation and its expression is lost in basal cell carcinomas. Mol Cancer Res; 2005 Sep;3(9):483-92
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The candidate tumor suppressor gene ZAC is involved in keratinocyte differentiation and its expression is lost in basal cell carcinomas.
  • ZAC is a zinc finger transcription factor that induces apoptosis and cell cycle arrest in various cell lines.
  • The corresponding gene is maternally imprinted and localized on chromosome 6q24-q25, a region harboring an unidentified tumor suppressor gene for a variety of solid neoplasms.
  • ZAC expression is lost or down-regulated in some breast, ovary, and pituitary tumors and in an in vitro model of ovary epithelial cell transformation.
  • In the present study, we examined ZAC expression in normal skin and found a high expression level in basal keratinocytes and a lower, more heterogeneous, expression in the first suprabasal differentiating layers of epidermis.
  • Interestingly, we found a dramatic loss of ZAC expression in basal cell carcinoma, a neoplasm characterized by a relatively undifferentiated morphology.
  • In contrast, ZAC expression was maintained in squamous cell carcinomas that retain the squamous differentiated phenotype.
  • [MeSH-major] Cell Cycle Proteins / metabolism. Cell Differentiation. Keratinocytes / cytology. Skin Neoplasms / metabolism. Transcription Factors / metabolism
  • [MeSH-minor] Carcinoma, Basal Cell / genetics. Carcinoma, Basal Cell / metabolism. Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Cells, Cultured. Genes, Tumor Suppressor. Humans. In Situ Hybridization. RNA Probes. Tumor Suppressor Proteins. Zinc Fingers

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16179495.001).
  • [ISSN] 1541-7786
  • [Journal-full-title] Molecular cancer research : MCR
  • [ISO-abbreviation] Mol. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / PLAGL1 protein, human; 0 / RNA Probes; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


84. Huang SW, Liu KT, Chang CC, Chen YJ, Wu CY, Tsai JJ, Lu WC, Wang YT, Liu CM, Shieh JJ: Imiquimod simultaneously induces autophagy and apoptosis in human basal cell carcinoma cells. Br J Dermatol; 2010 Aug;163(2):310-20
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imiquimod simultaneously induces autophagy and apoptosis in human basal cell carcinoma cells.
  • BACKGROUND: Imiquimod shows antitumour activity through the stimulation of cell-mediated immunity in vivo.
  • Recent studies have shown that imiquimod promotes apoptosis in melanoma cells and induces autophagy in macrophage cell lines.
  • OBJECTIVES: To evaluate the imiquimod-induced apoptosis, autophagy and their relationship in a basal cell carcinoma (BCC) cell line.
  • METHODS: Cell viability was determined by XTT test.
  • Both apoptosis and autophagy induced by imiquimod cooperate to cause BCC cell death.
  • However, inhibition of imiquimod-induced apoptosis increased the strength of autophagy, and inhibition of imiquimod-induced autophagy further promoted cell apoptosis.
  • CONCLUSIONS: This study not only demonstrates that imiquimod can directly induce autophagy and apoptosis in BCC cells, but also shows the cooperation and coordination between these two processes to induce cell death.
  • [MeSH-major] Aminoquinolines / pharmacology. Antineoplastic Agents / pharmacology. Apoptosis. Autophagy. Carcinoma, Basal Cell / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Caspase Inhibitors. Caspases / metabolism. Cell Line, Tumor / drug effects. Dose-Response Relationship, Drug. Humans. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20426785.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / Caspase Inhibitors; 99011-02-6 / imiquimod; EC 3.4.22.- / Caspases
  •  go-up   go-down


85. Schwartzberg JB, Elgart GW, Romanelli P, Fangchao M, Federman DG, Kirsner RS: Accuracy and predictors of basal cell carcinoma diagnosis. Dermatol Surg; 2005 May;31(5):534-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Accuracy and predictors of basal cell carcinoma diagnosis.
  • BACKGROUND: Basal cell carcinoma (BCC) is the most common cancer in the United States.
  • We also sought to determine which clinical and historical factors most influence a dermatologist's perception that a tumor is a BCC and to determine which factors are correlated with a lesion being a BCC.
  • [MeSH-major] Carcinoma, Basal Cell / diagnosis. Dermatology / standards. Practice Patterns, Physicians' / standards. Skin Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15962736.001).
  • [ISSN] 1076-0512
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


86. Fukunaga M: Cutaneous spindle cell carcinoma following basal cell carcinoma. Am J Dermatopathol; 2005 Feb;27(1):17-20
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous spindle cell carcinoma following basal cell carcinoma.
  • A spindle cell carcinoma arose three years after the seeming excision of a so-called "infiltrative" basal cell carcinoma (IBCC) in the cheek of an 87-year-old Japanese woman.
  • The tumor was composed of short fascicles and whorling arrangements of spindle to polygonal cells without residual IBCC.
  • Immunohistochemically, the tumor was positive for vimentin, cytokeratin 8 & 18, epithelial membrane antigen, and alpha-smooth muscle actin.
  • Ultrastructurally, the tumor cells had tonofilaments and desmosomes.
  • This case and others support the concept that spindle cell carcinoma can pursue an aggressive clinical course.
  • [MeSH-major] Carcinoma / pathology. Carcinoma, Basal Cell / pathology. Neoplasms, Second Primary. Skin Neoplasms / pathology
  • [MeSH-minor] Actins / analysis. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Fatal Outcome. Female. Humans. Keratins / analysis. Mucin-1 / analysis. Vimentin / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Dermatopathol. 2005 Dec;27(6):546; author reply 546 [16314711.001]
  • (PMID = 15677971.001).
  • [ISSN] 0193-1091
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actins; 0 / Biomarkers, Tumor; 0 / Mucin-1; 0 / Vimentin; 68238-35-7 / Keratins
  •  go-up   go-down


87. Orlov MD, Chernyavsky AI, Arredondo J, Grando SA: Synergistic actions of pemphigus vulgaris IgG, Fas-ligand and tumor necrosis factor-alpha during induction of basal cell shrinkage and acantholysis. Autoimmunity; 2006 Nov;39(7):557-62
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synergistic actions of pemphigus vulgaris IgG, Fas-ligand and tumor necrosis factor-alpha during induction of basal cell shrinkage and acantholysis.
  • This study tested a recently proposed "Basal Cell Shrinkage" hypothesis of pemphigus acantholysis through a quantitative analysis of individual and cooperative effects of pemphigus vulgaris (PV) IgG, Fas-ligand (Fas-L) and tumor necrosis factor-alpha (TNFalpha) on keratinocyte (KC) volume (i.e. cell size) and adhesive properties.
  • Within 12-24 h of exposure, basal cells in experimental cultures lost their ability to form stress fibers, retracted cytoplasmic aprons and formed keratin aggregates, indicating that their cytoskeleton collapsed.
  • The cell volume decreased significantly (p < 0.05) as the polygonal cell shape changed to a round one.
  • Since in the skin of PV patients, KCs are targeted by autoantibodies concomitantly with being exposed to autocrine and paracrine pro-apoptotic and pro-inflammatory cytokines, we combined PV IgG with Fas-L and/or TNFalpha in the cell culture experiments.
  • This amplified several fold an ability of PV IgG to cause basal cell shrinkage and detachment.
  • The obtained results demonstrated for the first time that PV IgG works together with Fas-L and TNFalpha to induce acantholysis via basal cell shrinkage, which provides a novel mechanism explaining successful treatment of PV patients with TNFalpha inhibitors.
  • [MeSH-major] Acantholysis / immunology. Acantholysis / pathology. Fas Ligand Protein / physiology. Immunoglobulin G / physiology. Keratinocytes / immunology. Pemphigus / immunology. Pemphigus / pathology. Tumor Necrosis Factor-alpha / physiology
  • [MeSH-minor] Cell Death / immunology. Humans

  • Genetic Alliance. consumer health - Pemphigus.
  • Genetic Alliance. consumer health - Pemphigus vulgaris.
  • MedlinePlus Health Information. consumer health - Pemphigus.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Autoimmunity. 2006 Nov;39(7):521-30 [17135055.001]
  • (PMID = 17101499.001).
  • [ISSN] 0891-6934
  • [Journal-full-title] Autoimmunity
  • [ISO-abbreviation] Autoimmunity
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Fas Ligand Protein; 0 / Immunoglobulin G; 0 / Tumor Necrosis Factor-alpha
  •  go-up   go-down


88. High A, Zedan W: Basal cell nevus syndrome. Curr Opin Oncol; 2005 Mar;17(2):160-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell nevus syndrome.
  • PURPOSE OF REVIEW: Basal cell nevus syndrome (BCNS), is a hereditary condition transmitted as an autosomal dominant trait exhibiting high penetrance and variable expressivity.
  • Inherited or spontaneous mutations in the human homologue of the Drosophila patched gene underlie the disorder and in addition to tumor predisposition, are associated with a range of 'patterning' defects.
  • These developmental abnormalities occur as a result of haplo-insufficiency in heterozygotes for the mutated gene, whereas neoplastic complications arise from a classical two-hit tumor suppressor gene model.
  • [MeSH-major] Basal Cell Nevus Syndrome / etiology. Skin Neoplasms / etiology

  • Genetic Alliance. consumer health - Nevus.
  • Genetics Home Reference. consumer health - Gorlin syndrome.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15725922.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Membrane Proteins
  • [Number-of-references] 59
  •  go-up   go-down


89. Chew R: Destruction of the orbit and globe by recurrence of basal cell carcinoma. Optometry; 2007 Jul;78(7):344-51

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Destruction of the orbit and globe by recurrence of basal cell carcinoma.
  • BACKGROUND: Basal cell carcinoma (BCC) is the most common skin malignancy and represents 90% of eyelid malignancies.
  • CASE REPORT: The patient described in this case report had basal cell carcinoma of the upper right lid 4 to 5 years prior to examination.
  • He had extensive surgery to remove the tumor and subsequent skin grafting.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Eyelid Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Orbit / pathology. Orbital Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Invasiveness. Ophthalmologic Surgical Procedures / methods. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17601572.001).
  • [ISSN] 1529-1839
  • [Journal-full-title] Optometry (St. Louis, Mo.)
  • [ISO-abbreviation] Optometry
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


90. Liu A, Wei L, Gardner WA, Deng CX, Man YG: Correlated alterations in prostate basal cell layer and basement membrane. Int J Biol Sci; 2009;5(3):276-85
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlated alterations in prostate basal cell layer and basement membrane.
  • Our recent studies revealed that focal basal cell layer disruption (FBCLD) induced auto-immunoreactions represented a contributing factor for human prostate tumor progression and invasion.
  • As the basement membrane surrounds and attaches to the basal cell layer, our current study assessed whether FBCLD would impact the physical integrity of the associated basement membrane.
  • Paraffin sections from 25-human prostate tumors were subjected to double immunohistochemistry to simultaneously elucidate the basal cell layer and the basement membrane with corresponding biomarkers.
  • The basement membrane in all or nearly all ducts or acini with p63 positive basal cells was substantially thicker and more uniform than that in ducts or acini without p63 positive basal cells, and also, a vast majority of the focal disruptions occurred near basal cells that lack p63 expression.
  • These findings suggest that focal disruptions in the basal cell layer and alterations in the basement membrane are correlated events and that the physical and functional status of the basal cells could significantly impact the physical integrity of the overlying basement membrane.
  • As the degradation of both the basal cell layer and the basement membrane is a pre-requisite for prostate tumor invasion or progression, ducts or acini with focally disrupted basal cell layer and basement membrane are likely at greater risk to develop invasive lesions.
  • Thus, further elucidation of the specific molecules and mechanism associated with these events may lead to the development of a more effective alternative for repeat biopsy to monitor tumor progression and invasion.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anticancer Res. 1994 Nov-Dec;14(6B):2465-72 [7872668.001]
  • [Cites] J Urol. 1995 Nov;154(5):1791-4 [7563348.001]
  • [Cites] Crit Rev Eukaryot Gene Expr. 1995;5(1):1-77 [7549180.001]
  • [Cites] Hum Pathol. 1995 Dec;26(12):1291-2 [8522299.001]
  • [Cites] Prostate. 1996 Feb;28(2):98-106 [8604398.001]
  • [Cites] Cancer. 1996 Jul 15;78(2):330-6 [8674012.001]
  • [Cites] CA Cancer J Clin. 1997 Jan-Feb;47(1):5-27 [8996076.001]
  • [Cites] J Urol. 1997 Jul;158(1):12-22 [9186314.001]
  • [Cites] Nat Med. 1997 Aug;3(8):927-30 [9256288.001]
  • [Cites] Pathologe. 1998 Jan;19(1):12-20 [9541938.001]
  • [Cites] Br J Cancer. 1998 Jul;78(1):46-9 [9662249.001]
  • [Cites] J Surg Res. 1999 Jan;81(1):42-7 [9889056.001]
  • [Cites] Am J Clin Pathol. 1999 Jul;112(1):69-74 [10396288.001]
  • [Cites] J Urol. 2005 Jan;173(1):10-20 [15592017.001]
  • [Cites] Cancer Detect Prev. 2005;29(2):161-9 [15829376.001]
  • [Cites] Eur Urol. 2005 Sep;48(3):379-85 [15961218.001]
  • [Cites] Cancer Res. 2005 Oct 1;65(19):8583-6 [16204020.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 27;102(52):19093-6 [16361440.001]
  • [Cites] Cancer Res. 2006 Feb 15;66(4):2028-37 [16489002.001]
  • [Cites] Br J Cancer. 2006 Jul 17;95(2):164-71 [16804520.001]
  • [Cites] J Urol. 2006 Sep;176(3):1012-6 [16890681.001]
  • [Cites] Pathol Res Pract. 2006;202(9):651-62 [16842934.001]
  • [Cites] Cancer Res. 2007 Jun 15;67(12):5737-46 [17575140.001]
  • [Cites] Med Hypotheses. 2008;70(2):387-408 [17658698.001]
  • [Cites] Int J Biol Sci. 2008;4(4):246-58 [18725981.001]
  • [Cites] Semin Urol Oncol. 1999 Nov;17(4):187-98 [10632120.001]
  • [Cites] Prostate. 2000 Sep 1;44(4):265-70 [10951489.001]
  • [Cites] Gynecol Oncol. 2004 Jan;92(1):47-56 [14751137.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jul 20;101(29):10721-5 [15249662.001]
  • [Cites] Cell. 2004 Aug 6;118(3):277-9 [15294153.001]
  • [Cites] J Cell Physiol. 2004 Nov;201(2):266-76 [15334661.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):5963-72 [15342375.001]
  • [Cites] Development. 2004 Oct;131(20):4955-64 [15371309.001]
  • [Cites] Lab Invest. 1983 Aug;49(2):140-7 [6348406.001]
  • [Cites] Semin Thromb Hemost. 1986 Oct;12(4):294-307 [3024322.001]
  • [Cites] J Urol. 1987 Jan;137(1):53-6 [2432282.001]
  • [Cites] Hum Pathol. 1988 Jan;19(1):119-20 [3335387.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1991;418(5):375-81 [2035251.001]
  • [Cites] Prostate Suppl. 1992;4:71-7 [1374179.001]
  • [Cites] J Neurosci. 2000 Oct 1;20(19):7377-83 [11007896.001]
  • [Cites] Am J Pathol. 2000 Dec;157(6):1769-75 [11106548.001]
  • [Cites] Scand J Urol Nephrol Suppl. 2000;(205):44-9 [11144903.001]
  • [Cites] Cell Mol Life Sci. 2001 Jul;58(8):1150-8 [11529507.001]
  • [Cites] J Cell Physiol. 2001 Nov;189(2):189-96 [11598904.001]
  • [Cites] Clin Cancer Res. 2002 May;8(5):1172-7 [12006534.001]
  • [Cites] Ann N Y Acad Sci. 2002 Jun;963:156-68 [12095941.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 29;100(9):5401-6 [12702759.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):411-21 [12778131.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jun 24;100(13):7847-52 [12788977.001]
  • [Cites] Prostate Cancer Prostatic Dis. 2003;6(4):305-10 [14663472.001]
  • (PMID = 19343113.001).
  • [ISSN] 1449-2288
  • [Journal-full-title] International journal of biological sciences
  • [ISO-abbreviation] Int. J. Biol. Sci.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / PC / N02 PC051308
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / CKAP4 protein, human; 0 / Membrane Proteins
  • [Other-IDs] NLM/ PMC2664550
  • [Keywords] NOTNLM ; basement membrane / focal basal cell layer disruption / prostate tumors
  •  go-up   go-down


91. Ozcan C, Apa DD, Vayisoglu Y, Görür K: Unilateral parotid gland involvement with synchronous multiple Basal cell adenomas. J Craniofac Surg; 2007 Nov;18(6):1470-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unilateral parotid gland involvement with synchronous multiple Basal cell adenomas.
  • Basal cell adenoma (BCA) is a rare benign epithelial tumor of the salivary gland.
  • The most commonly seen multiple tumor unilaterally or bilaterally is the Warthin's tumor.
  • More extensive excision of the parotid gland tumor, careful macroscopic perioperative examination of the surgical specimen, and histologic evaluation of all surgical specimens might be necessary for reducing revision operations and surgical complications.
  • [MeSH-major] Adenoma / pathology. Neoplasms, Multiple Primary / pathology. Parotid Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17993904.001).
  • [ISSN] 1049-2275
  • [Journal-full-title] The Journal of craniofacial surgery
  • [ISO-abbreviation] J Craniofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


92. Papa G, Grandi G, Pascone M: Collision tumor of malignant skin cancers: a case of melanoma in basal cell carcinoma. Pathol Res Pract; 2006;202(9):691-4
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Collision tumor of malignant skin cancers: a case of melanoma in basal cell carcinoma.
  • The coexistence of two malignant skin tumors intermingling in the same histologic specimen is rare.
  • We report a case of melanoma in a basal cell carcinoma collision tumor.
  • The presence of two intermingled neoplasms was confirmed by immunohistochemistry, which showed strong positivity for S-100 and HMB-45.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Melanoma / pathology. Neoplasms, Multiple Primary / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Antigens, Neoplasm. Carcinoma, Squamous Cell / pathology. Cheek / pathology. Female. Humans. Immunohistochemistry. Melanoma-Specific Antigens. Neoplasm Proteins / metabolism. S100 Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16876964.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Melanoma-Specific Antigens; 0 / Neoplasm Proteins; 0 / S100 Proteins
  •  go-up   go-down


93. Mueller CK, Nicolaus K, Thorwarth M, Schultze-Mosgau S: Multivariate analysis of the influence of patient-, tumor-, and management-related factors on the outcome of surgical therapy for facial basal-cell carcinoma. Oral Maxillofac Surg; 2010 Sep;14(3):163-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multivariate analysis of the influence of patient-, tumor-, and management-related factors on the outcome of surgical therapy for facial basal-cell carcinoma.
  • PURPOSE: This retrospective, case-control study aimed at evaluating the influence of patient-, tumor-, and management-related factors on the outcome of surgical therapy for facial basal-cell carcinoma (BCC) employing a multivariate analysis.
  • RESULTS: Following surgical BCC treatment, age and tumor location in the area of the eyes, nose, lips, and ears were independent predictors of wound healing disorders.
  • Tumor location in the area of the eyes, nose, lips, and ears, subtype and class were independent predictors of recurrence.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Facial Neoplasms / surgery. Skin Neoplasms / surgery
  • [MeSH-minor] Age Factors. Aged. Case-Control Studies. Ear Neoplasms / surgery. Esthetics. Eye Neoplasms / surgery. Female. Follow-Up Studies. Forecasting. Humans. Lip Neoplasms / surgery. Male. Mohs Surgery. Multivariate Analysis. Neoplasm Recurrence, Local / pathology. Nose Neoplasms / surgery. Postoperative Complications. Quality of Life. Reconstructive Surgical Procedures / methods. Retrospective Studies. Sex Factors. Surgical Flaps. Treatment Outcome. Wound Healing

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jan 1;64(1):280-8 [16377416.001]
  • [Cites] Dermatol Surg. 2009 Sep;35(9):1349-54 [19500127.001]
  • [Cites] Int J Oral Maxillofac Surg. 2009 Nov;38(11):1194-200 [19716681.001]
  • [Cites] N Engl J Med. 2005 Nov 24;353(21):2262-9 [16306523.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Nov 1;57(3):803-12 [14529787.001]
  • [Cites] Eur J Orthod. 2006 Jun;28(3):274-81 [16415084.001]
  • [Cites] Skin Res Technol. 2009 Aug;15(3):357-63 [19624433.001]
  • [Cites] J Oral Maxillofac Surg. 1996 Mar;54(3):297-302; discussion 302-3 [8600236.001]
  • [Cites] Br J Dermatol. 2008 Jul;159(1):35-48 [18593385.001]
  • [Cites] Br J Plast Surg. 2002 Jun;55(4):293-7 [12160534.001]
  • [Cites] Coll Antropol. 2007 Jan;31 Suppl 1:91-6 [17469760.001]
  • [Cites] Quintessence Int. 2005 Nov-Dec;36(10):759-69 [16261792.001]
  • [Cites] Br J Plast Surg. 2002 Dec;55(8):616-22 [12550113.001]
  • [Cites] Arch Facial Plast Surg. 2007 Sep-Oct;9(5):344-51 [17875828.001]
  • [Cites] J Dtsch Dermatol Ges. 2009 Dec;7(12):1075-82; quiz 1083 [19456852.001]
  • [Cites] Radiother Oncol. 2009 Dec;93(3):581-5 [19733409.001]
  • [Cites] Plast Reconstr Surg. 2004 Jun;113(7):2006-11 [15253190.001]
  • [Cites] J Invest Dermatol. 2004 Oct;123(4):634-8 [15373766.001]
  • [Cites] J Am Acad Dermatol. 2001 Feb;44(2):224-30 [11174379.001]
  • [Cites] Lancet. 2004 Nov 13-19;364(9447):1766-72 [15541449.001]
  • [Cites] Lancet Oncol. 2008 Dec;9(12):1149-56 [19010733.001]
  • [Cites] J Surg Res. 2010 May 15;160(2):340-8 [19394654.001]
  • (PMID = 20349095.001).
  • [ISSN] 1865-1569
  • [Journal-full-title] Oral and maxillofacial surgery
  • [ISO-abbreviation] Oral Maxillofac Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


94. Tjiu JW, Chen JS, Shun CT, Lin SJ, Liao YH, Chu CY, Tsai TF, Chiu HC, Dai YS, Inoue H, Yang PC, Kuo ML, Jee SH: Tumor-associated macrophage-induced invasion and angiogenesis of human basal cell carcinoma cells by cyclooxygenase-2 induction. J Invest Dermatol; 2009 Apr;129(4):1016-25
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor-associated macrophage-induced invasion and angiogenesis of human basal cell carcinoma cells by cyclooxygenase-2 induction.
  • Tumor-associated macrophages (TAMs) and cyclooxygenase-2 (COX-2) are associated with invasion, angiogenesis, and poor prognosis in many human cancers.
  • However, the role of TAMs in human basal cell carcinoma (BCC) remains elusive.
  • We found that the number of TAMs infiltrating the tumor is correlated with the depth of invasion, microvessel density, and COX-2 expression in human BCC cells.
  • TAMs also aggregate near COX-2 expressing BCC tumor nests.
  • Human THP-1 cell line cells, after treated with phorbol myristate acetate (PMA), differentiated to macrophages with M2 functional profiles.
  • [MeSH-major] Carcinoma, Basal Cell / blood supply. Carcinoma, Basal Cell / pathology. Cyclooxygenase 2 / biosynthesis. Macrophages / physiology. Neovascularization, Pathologic / etiology. Skin Neoplasms / blood supply. Skin Neoplasms / pathology
  • [MeSH-minor] Cell Line, Tumor. Cell Polarity. Enzyme Induction. Fibroblast Growth Factor 2 / biosynthesis. Humans. Matrix Metalloproteinase 9 / biosynthesis. NF-kappa B / metabolism. Neoplasm Invasiveness. Tetradecanoylphorbol Acetate / pharmacology. Vascular Endothelial Growth Factor A / biosynthesis. p38 Mitogen-Activated Protein Kinases / metabolism

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. 12-O-TETRADECANOYLPHORBOL-13-ACETATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18843292.001).
  • [ISSN] 1523-1747
  • [Journal-full-title] The Journal of investigative dermatology
  • [ISO-abbreviation] J. Invest. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / NF-kappa B; 0 / Vascular Endothelial Growth Factor A; 103107-01-3 / Fibroblast Growth Factor 2; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases; EC 3.4.24.35 / Matrix Metalloproteinase 9; NI40JAQ945 / Tetradecanoylphorbol Acetate
  •  go-up   go-down


95. Howell BG, Solish N, Lu C, Watanabe H, Mamelak AJ, Freed I, Wang B, Sauder DN: Microarray profiles of human basal cell carcinoma: insights into tumor growth and behavior. J Dermatol Sci; 2005 Jul;39(1):39-51
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microarray profiles of human basal cell carcinoma: insights into tumor growth and behavior.
  • PURPOSE: Basal cell carcinoma (BCC) is the most common human neoplasm.
  • These covered a range of categories, including extracellular matrix, cell junctions, motility, metastasis, oncogenes, tumor suppressors, DNA repair, cell cycle, immune regulation and angiogenesis.
  • [MeSH-major] Carcinoma, Basal Cell / genetics. Carcinoma, Basal Cell / pathology. Gene Expression Profiling. Skin Neoplasms / genetics. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15978418.001).
  • [ISSN] 0923-1811
  • [Journal-full-title] Journal of dermatological science
  • [ISO-abbreviation] J. Dermatol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Caveolin 1; 0 / Caveolins; 0 / DNA-Binding Proteins; 0 / GLI2 protein, human; 0 / Kruppel-Like Transcription Factors; 0 / Nuclear Proteins; 68238-35-7 / Keratins; 9007-34-5 / Collagen; EC 3.1.3.16 / Phosphoprotein Phosphatases
  •  go-up   go-down


96. Asplund A, Sivertsson A, Bäckvall H, Ahmadian A, Lundeberg J, Ponten F: Genetic mosaicism in basal cell carcinoma. Exp Dermatol; 2005 Aug;14(8):593-600
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic mosaicism in basal cell carcinoma.
  • Human basal cell cancer (BCC) shows unique growth characteristics, including a virtual inability to metastasize, absence of a precursor stage and lack of tumour progression.
  • The clonal nature of BCC has long been a subject for debate because of the tumour growth pattern.
  • Four parts of each individual tumour plus isolated samples of stroma were analysed following laser-assisted microdissection.
  • In 12/13 tumours, the epithelial component of the tumour showed a monoclonal pattern suggesting a unicellular origin.
  • Surprisingly, one tumour showed evidence of being composed of at least two non-related monoclonal clones.
  • This finding was supported by the analysis of the ptch and p53 gene.
  • Clonality analysis of tumour stroma showed both mono- and polyclonal patterns.
  • The study results show that what appears to be one tumour may occasionally constitute two or more independent tumours intermingled or adjacent to each other, possibly reflecting a local predisposition to malignant transformation.
  • [MeSH-major] Carcinoma, Basal Cell / genetics. Cell Transformation, Neoplastic. Mosaicism. Neoplasms, Glandular and Epithelial / genetics. Receptors, Androgen / genetics
  • [MeSH-minor] Chromosome Aberrations. Chromosomes, Human, X. DNA / metabolism. Disease Progression. Dosage Compensation, Genetic. Epidermis / metabolism. Epithelium / metabolism. Female. Heterozygote. Humans. Lasers. Loss of Heterozygosity. Tumor Suppressor Protein p53 / metabolism

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16026581.001).
  • [ISSN] 0906-6705
  • [Journal-full-title] Experimental dermatology
  • [ISO-abbreviation] Exp. Dermatol.
  • [Language] eng
  • [Databank-accession-numbers] OMIM/ 109400
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / AR protein, human; 0 / Receptors, Androgen; 0 / Tumor Suppressor Protein p53; 9007-49-2 / DNA
  •  go-up   go-down


97. Kanitakis J, Chouvet B: Granular-cell basal cell carcinoma of the skin. Eur J Dermatol; 2005 Jul-Aug;15(4):301-3
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granular-cell basal cell carcinoma of the skin.
  • Granular cell basal cell carcinoma (GBCC) is a very rare variant of BCC, of which ten cases have been reported in the literature.
  • The tumor developed on the face of a 71-year old man and showed typical features of GBCC, i.e. a tumor reminiscent of nodular BCC consisting of cells with a granular eosinophilic cytoplasm.
  • Immunohistochemically, tumor cells expressed cytoplasmic reactivity for keratins, CD68 and CD15 antigens, bcl-2 oncoprotein and nuclear reactivity for the p63 protein.
  • [MeSH-major] Adenocarcinoma / diagnosis. Skin Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16048765.001).
  • [ISSN] 1167-1122
  • [Journal-full-title] European journal of dermatology : EJD
  • [ISO-abbreviation] Eur J Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 12
  •  go-up   go-down


98. Reisinger DM, Shiffer JD, Cognetta AB Jr, Chang Y, Moore PS: Lack of evidence for basal or squamous cell carcinoma infection with Merkel cell polyomavirus in immunocompetent patients with Merkel cell carcinoma. J Am Acad Dermatol; 2010 Sep;63(3):400-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lack of evidence for basal or squamous cell carcinoma infection with Merkel cell polyomavirus in immunocompetent patients with Merkel cell carcinoma.
  • BACKGROUND: Merkel cell polyomavirus (MCV) was discovered by digital transcriptome subtraction as a monoclonal infection of Merkel cell carcinoma (MCC) tumors.
  • OBJECTIVE: We sought to directly assay for MCV infection in squamous cell carcinoma (SCC) or basal cell carcinoma (BCC) tumor cells by immunostaining for viral antigen.
  • [MeSH-major] Carcinoma, Basal Cell / virology. Carcinoma, Merkel Cell / virology. Carcinoma, Squamous Cell / virology. Immunocompetence. Skin Neoplasms / virology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.
  • (PMID = 20584559.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA120726; United States / NCI NIH HHS / CA / CA136363
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Polyomavirus Transforming; 0 / DNA, Viral
  •  go-up   go-down


99. De Giorgi V, Salvini C, Chiarugi A, Paglierani M, Maio V, Nicoletti P, Santucci M, Carli P, Massi D: In vivo characterization of the inflammatory infiltrate and apoptotic status in imiquimod-treated basal cell carcinoma. Int J Dermatol; 2009 Mar;48(3):312-21
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vivo characterization of the inflammatory infiltrate and apoptotic status in imiquimod-treated basal cell carcinoma.
  • BACKGROUND: Imiquimod use in the treatment of basal cell carcinoma (BCC) has proven to be successful in a large percentage of cases, inducing tumor regression; however, the exact cellular mechanism has not been fully clarified.
  • AIM: To measure the morphological changes in the tumor microenvironment and the markers of apoptosis in skin biopsies from patients with BCC before and after imiquimod treatment.
  • METHODS: In this open label study, skin biopsies obtained from 11 patients with BCC were evaluated before and after imiquimod treatment for: (i) morphological changes in the tumor microenvironment, with specific emphasis on the immunophenotype of inflammatory cells around the tumor; and (ii) markers of apoptosis, including expression of death receptors.
  • An increase in the cytotoxic CD3(+)/CD8(+) T-cell population was also observed.
  • Imiquimod treatment was associated with a marked increased in CD20(+) B cells, and a less pronounced enhancement in cells of monocyte-macrophage origin (CD68(+)) surrounding, or within, the tumor.
  • This finding indicates either that macrophages play a minor role in the imiquimod-induced response, or the recruitment of these cells is related to time and dose.
  • Imiquimod treatment decreased CD1A(+) Langerhans cells in the epidermis and increased the number of CD1A(+) dendritic cells within the tumor aggregates.
  • [MeSH-major] Aminoquinolines / administration & dosage. Antineoplastic Agents / administration & dosage. Carcinoma, Basal Cell / drug therapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. Imiquimod .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19261026.001).
  • [ISSN] 1365-4632
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antigens, CD3; 0 / Antigens, CD4; 0 / Antineoplastic Agents; 0 / Ointments; 99011-02-6 / imiquimod
  •  go-up   go-down


100. Kunte C, Konz B: [Current recommendations in the treatment of basal cell carcinoma and squamous cell carcinoma of the skin]. Hautarzt; 2007 May;58(5):419-26
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Current recommendations in the treatment of basal cell carcinoma and squamous cell carcinoma of the skin].
  • The incidence of the most common tumors of the skin, basal cell carcinoma and squamous cell carcinoma, has risen rapidly in recent years.
  • They must be able to develop therapeutic strategies adapted to the tumor and the patient.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / surgery. Facial Neoplasms / surgery. Skin Neoplasms / surgery
  • [MeSH-minor] Combined Modality Therapy. Humans. Neoplasm Invasiveness. Neoplasm, Residual / pathology. Neoplasm, Residual / radiotherapy. Neoplasm, Residual / surgery. Prognosis. Radiotherapy, Adjuvant. Skin / pathology. Surgical Flaps

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Strahlenther Onkol. 2001 May;177(5):240-6 [11398609.001]
  • [Cites] Facial Plast Surg. 1997 Apr;13(2):79-82 [9243982.001]
  • [Cites] Hautarzt. 2005 May;56(5):430-40 [15815888.001]
  • [Cites] J Am Acad Dermatol. 2004 May;50(5):722-33 [15097956.001]
  • [Cites] J Dermatol Surg Oncol. 1994 May;20(5):350 [8176049.001]
  • [Cites] Recent Results Cancer Res. 2002;160:219-24 [12079216.001]
  • [Cites] Cancer. 1997 Mar 1;79(5):915-9 [9041153.001]
  • [Cites] BMJ. 2004 Sep 25;329(7468):705 [15364703.001]
  • [Cites] Dermatol Surg. 2000 Aug;26(8):759-64 [10940063.001]
  • [Cites] Br J Dermatol. 2000 Apr;142(4):752-7 [10792227.001]
  • [Cites] Int J Cancer. 1999 May 17;81(4):555-9 [10225444.001]
  • [Cites] Acta Derm Venereol. 2004;84(3):218-22 [15202839.001]
  • [Cites] J Am Acad Dermatol. 2007 Jan;56(1):91-5 [17190625.001]
  • [Cites] Br J Dermatol. 2006 Jun;154(6):1202-3 [16704658.001]
  • [Cites] Lancet. 1988 Apr 9;1(8589):795-7 [2895318.001]
  • [Cites] Dermatol Surg. 2006 Nov;32(11):1309-21 [17083582.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2006 Sep;20(8):926-30 [16922939.001]
  • [Cites] J Dtsch Dermatol Ges. 2006 Mar;4(3):260-2 [16626324.001]
  • [Cites] J Dermatol Surg Oncol. 1991 Jul;17(7):574-8 [1860987.001]
  • [Cites] Br J Cancer. 1997;76(1):100-6 [9218740.001]
  • [Cites] Arch Dermatol. 2004 Oct;140(10 ):1286-7 [15492202.001]
  • [Cites] Hautarzt. 1975 Dec;26(12):647-50 [1213885.001]
  • [Cites] Dermatol Surg. 2004 Apr;30(4 Pt 2):642-50 [15061849.001]
  • [Cites] J Dtsch Dermatol Ges. 2006 May;4(5):441-3 [16686614.001]
  • [Cites] Hautarzt. 1995 Sep;46(9):607-14 [7591764.001]
  • [Cites] J Am Acad Dermatol. 2007 Jan;56(1):125-43 [17190630.001]
  • [Cites] J Am Acad Dermatol. 2003 Sep;49(3):483-6 [12963913.001]
  • [Cites] Eur J Dermatol. 2002 Nov-Dec;12 (6):569-72 [12459530.001]
  • [Cites] Br J Dermatol. 2002 Dec;147(6):1227-36 [12452875.001]
  • [Cites] Recent Results Cancer Res. 2002;160:240-5 [12079219.001]
  • (PMID = 17443305.001).
  • [ISSN] 0017-8470
  • [Journal-full-title] Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete
  • [ISO-abbreviation] Hautarzt
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 31
  •  go-up   go-down






Advertisement